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Abstract 
 
This study commenced with an investigation into a total synthesis of the antibiotic 
platensimycin 1.1 in chapter one. The key reaction for accessing the synthetically 
challenging fused ring system involved a meta-photocycloaddition reaction and the 
chapter one describes our attempts at the syntheses of the key substrates. Much of the 
chemistry was unsuccessful however we were able to attempt a key photochemical 
reaction however the desired compound was not obtained. On the basis of these 
outcomes we refocused our efforts towards the syntheses of kainic acid 2.1 and 
allokaininc acid 2.2 in chapter two. 
 
 
 
VI 
 
We aimed to devise a stereoselective synthesis of both kainic acid 2.1 and the allokainic 
acid 2.2, utilising the diastereofacial selectivity inherent in the previously synthesised 
oxazolidinone 2.240. Oxazolidinone 2.240 was subjected to a stereo and regiocontrolled 
1,3-dipolar cycloaddition to give isoxazole 2.279. Reduction, followed by dehydration 
of isoxazole 2.279 gave the enone 2.287 which forms the Michael acceptor in the key 
Michael addition reaction. The 1,4 addition on enone 2.287, gave the two diastereomers 
2.328 and 2.329 which underwent sequential Wittig reaction, and Krapcho 
decarboxylation to give the formal synthesis of allokainic acid 2.2 and epikainate 2.346 
respectively. An investigation was also conducted with the aim of altering the 
stereochemistry of the dicarboxylic group in compound 2.329, in order to produce a 
novel route to the stereoselective synthesis of kainic acid 2.1.  
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1.1. Introduction 
Platensimycin 1.1 is a novel broad spectrum Gram-positive antibiotic used in antibiotic 
research due to its unique functional pattern and significant antibacterial activity.
1,2
  
 
 
Figure 1.1: Platensimycin. 
 
According to Wang,
1
 platensimycin demonstrates strong, broad-spectrum Gram-positive 
antibacterial activity by selectively inhibiting cellular lipid biosynthesis. This anti-
bacterial effect is exerted through the selective targeting of β-ketoacyl-(acyl-carrier-
protein (ACP)) synthase I/II (FabF/B) in the synthetic pathway of fatty acids. Treatment 
with platensimycin in mice eradicates Staphylococcus aureus infection.
1,2
 The first total 
synthesis of platensimycin 1.1 has been published by K.C. Nicolaou which involves the 
syntheses of a key dienone intermediate 1.2 prepared using a multi-step procedure.
3 
 
 
Figure 1.2: Nicolaou’s dienone intermediate. 
 
We developed two strategies for the synthesis of platensimycin 1.1 which are relatively 
short and will provide a range of analogues for biological screening. Both the strategies 
involve meta-photocycloaddition reaction
4
. The first meta-photocyloaddition reaction 
was reported by Wilzbach and Kaplan and Bryce-Smith, Gilbert and Orger in 1966.
4
 
The meta-photocyloaddition reaction is a photochemically induced cycloadditon of an 
alkene across a benzene derivative, which gives rise to a complex tricyclic fused ring 
2 
 
system. The meta-photocycloaddition reaction between ethane and benzene can be 
represented in three different forms shown below (scheme 1.1). 
 
 
 
Scheme 1.1: meta-photocycloaddition of benzene and ethane. 
 
While the meta-photocycloaddition of benzene is very well documented in the literature 
and has been used many times in organic synthesis, the mechanism has still not been 
fully elucidated. Generally it is thought that the reaction proceeds via the excitation of 
the benzene ring to its first singlet state (s1) by irradiation with 254 nm UV light which 
in turn forms an arene-alkene exciplex (scheme 1.2) 
 
 
Scheme 1.2: General mechanism of meta-photocycloaddition. 
 
During the meta-photocycloaddition as the reaction proceeds, the complex 1.3 is 
polarised with positive charge at position 1, with an allylically distributed negative 
charge between positions 3 and 5 when the allene undergoes 2,6-addition. As the 
alkene-arene bonds are formed a biradical intermediate 1.4 has been proposed in the 
formation of compounds 1.5 and 1.6 (scheme 1.2). 
3 
 
1.2. Retrosynthetic analysis for platensimycin 1.1. 
In the first approach to platensimycin 1.1 a meta-photocycloaddition reaction will be 
employed to secure the framework of the title compound. The retrosynthetic analysis for 
1.1 is shown below (scheme 1.3). 
 
 
Scheme 1.3:  Retrosynthetic analysis for platensimycin 1.1. 
 
In the first approach the tricyclic compound 1.7 is synthesised by an intramolecular 
meta-photocycloaddition of aromatic compound 1.8 and try to form the tricyclic core of 
the platensimycin 1.1 using compound 1.7. The synthesis of 1.7 from 1.8 is shown in a 
stepwise manner above (scheme 1.3). After the successful formation of the tricyclic core 
1.7 we shall try to attach the aromatic ring to form the total synthesis of platensimycin 
1.1. 
In another approach we shall synthesize the tricyclic core 1.7 of platensimycin 1.1 by 
using the retrosynthesis shown above (scheme 1.4). 
4 
 
 
Scheme 1.4: Retrosynthetic analysis for precursor 1.7. 
 
The aim is to synthesize 1.7 by the radical cyclisation of the triene 1.14. The proposed 
retrosynthesis for the triene 1.14 by using 1,6-dibromo-cyclohexene 1.15 is seen below 
(scheme 1.5). 
                                                        
 
Scheme 1.5: Retrosynthesis for 1.14 
 
The molecule 1.15 was difficult to synthesize as it is an unstable compound and we 
were having very difficult time in isolating the compound. A rapid approach for the 
synthesis of 1.15 was done by utilising the procedure involved in the rearrangement of 
6,6-dibromobicyclo[3.1.0]hexane
5
 1.17. 
 
1.3. Synthesis of 1,6-dibromo-cyclohexene 1.15. 
 
 
Scheme 1.6: Synthesis of 1,6-dibromo cyclohexene 1.15. 
5 
 
6,6-Dibromobicyclo[3.1.0]hexane  1.17 was obtained when the reaction product from 
cyclopentene 1.16 and dibromomethane was distilled rapidly at low temperature. A 
subsequent experiment showed that the 6,6-dibromide 1.17, in the absence of solvent, 
undergoes isomerisation to the 1,6-dibromo-cyclohexene 1.15 when heated at 155 
o
C 
for a short time (scheme 1.6). We could not isolate the compound even after several 
attempts. We could not get the compound even after high vaccum distillation. We 
abandoned this scheme and moved on to another method involving cyclohexenone 1.18 
(scheme 1.7). 
 
 
Reagents and conditions: i. Br2, DCM, Et3N, 0 
o
C - rt, 3 h, 72%; ii. CeCl3·7H2O/MeOH, NaBH4, DCM, 
rt, 1 h, 80%; 
Scheme 1.7: Synthesis of 2-bromo-cyclohex-2-enol 1.20. 
 
Cyclohexenone 1.18 was readily converted into 2-bromo-cyclohex-2-enone 1.19 by 
bromination using bromine in the presence of triethylamine. 2-Bromo-cyclohex-2-enone 
1.19 was reduced to 2-bromo-cyclohex-2-enol 1.20 by utilizing NaBH4 and cerium salt 
involving Luche’s reduction6,7 (scheme 1.7). An unsuccessful attempt to the formation 
of dibromide 1.15 from 2-bromo-cyclohex-2-enol 1.20 (scheme 1.8) can be seen below 
in table 1.1. 
 
 
Scheme 1.8: Bromination of 1.20. 
 
 
6 
 
Table 1.1: Bromination of 1.20 under different reaction conditions. 
 
S.No  Reactant Reagents and Conditions (i) Product 1.15 Inference 
1  1.20 PBr3, HBr, DCM, rt, 7 h. Nil Starting 
material 
recovered. 
2  1.20 CF3COOH, PBr3, HBr, DCM, rt,     
12 h. 
Nil Starting 
material 
recovered. 
3  1.20 CF3COOH, Ag Salts, PBr3, HBr, 
DCM, rt, 12 h. 
Nil Starting 
material 
recovered. 
 
 
1.4. Second approach for the synthesis of triene 1.14. 
 
 
Scheme 1.9: Retrosynthesis of 1.14 using 1.22. 
 
After an unsuccessful attempt to convert the 2-bromo-cyclohex-2-enol 1.20 to 1,6-
dibromo-cyclohexene 1.15 under various reaction conditions (scheme 1.8), we 
envisaged a new scheme for the synthesis of triene 1.14 utilising 1.22 (scheme 1.9). In 
the process of formation of diene 1.22 we unsuccessfully tried to utilise Wittig reaction 
conditions on bromocyclohexenone 1.19. The compound 1.19 decomposed (scheme 
1.10).  
7 
 
 
Reagents and conditions: i. n-BuLi (2.5M), -78 
o
C, Ph3P(CH2MeO)Br/THF; 
Scheme 1.10: Wittig reaction on bromo-cyclohexenone 1.19. 
 
At this stage we attempted to use the same conditions used above (scheme 1.10) on 
cyclohexeneone 1.18. We failed to obtain any desired results (scheme 1.11). The failure 
of Wittig reactions can be due to conjugated double bond with the carbonyl group in 
1.19 and 1.18. Usually the reaction would be successful if there is no conjugated double 
bond involved with the carbonyl group. 
 
 
Reagents and conditions: i. n-BuLi (2.5M), -78 
o
C, Ph3P(CH2MeO)Br/THF; 
Scheme 1.11: Wittig reaction on cyclohexenone 1.18. 
 
 
 
1.5. Photochemical approach for the total synthesis of platensimycin 1.1. 
We envisaged a scheme wherein the aromatic compound 1.8 would undergo 
intramolecular meta-photocycloaddition to form the tricyclic core of the platensimycin 
1.1. The compound 1.8 could be obtained by utilising methyl anisole 1.24 (scheme 
1.12).  
8 
 
 
 
Scheme 1.12: Retrosynthesis of 1.8. 
 
Methyl anisole 1.24 did not undergo otholithiation with 1.25. The electrophilic aromatic 
substitution reaction failed to yield any desired result (scheme 1.13). 
 
 
 
Reagents and conditions: i. n-BuLi (2.5M), -78 
o
C, then 1.25, THF, 6 h; 
Scheme 1.13: Substitution reaction on methylanisole 1.24. 
 
 
 
1.5.1. Synthesis of 1.27 and photochemistry using allene gas 1.11. 
At this stage a rapid approach to platensimycin 1.1 was attempted by using 
tetralin/allene photochemistry (scheme 1.14). A novel photochemical approach to 
platensimycin 1.1 was obtained using trisubstituted decalin 1.27. A meta-
photocycloaddition
4
 reaction between allene 1.11 and aromatic benzene ring of 1.27 
would give the tetracyclic compound 1.29. The reaction proceeds via the excitation of 
the benzene ring of 1.29 to its first singlet state (s1) by irradiation with UV light which 
in turn forms an arene-alkene exciplex 1.28 (scheme 1.14) to give tetracyclic complex 
1.29. 
9 
 
 
Scheme 1.14: Photochemistry of 1.27 using allene gas 1.11. 
 
5-Methoxy tetralone 1.30 would undergo addition of methyl group through Grignard’s 
reagent followed by elimination of water to give 8-methoxy methyl tetralin 1.31. The 
compound 1.31 would undergo further hydroboration to give trisubsituted decalin 1.32 
(scheme 1.15). The structure of 1.32 was confirmed by X-ray crystallographic studies 
(figure 1.3). 
 
Reagents and conditions: i. CH3MgBr, THF, Δ, 1 h; ii.  p-TSA/toluene, H2O, 1 h; iii. BH3·THF, NaOH, 
35% H2O2, 74% (overall yield); 
Scheme 1.15: Synthesis of 1.32. 
 
Figure 1.3: X-ray crystallographic structure of 1.32.  
10 
 
 
 
Reagents and conditions: i. TBSCl, Imidazole, DCM, 80%. ii. allene gas 1.11, CH3CN, hv(16w UV 
lamp); 
Scheme 1.16: Photochemistry 1.27 using allene gas. 
 
The compound 1.32 undergoes OH protection using TBSCl to give 1.27 which was 
dissolved in CH3CN. Allene gas 1.11 was dissolved in CH3CN and the gas was pumped 
using syringe from the allene gas 1.11 cylinder. The photochemical reaction was carried 
out using a 16w U.V lamp and the reaction mixture was subjected to photolysis (scheme 
1.14). The photolysis was observed in 30 mins, 60 mins, and after that in 1 h intervals. 
There was no change in the aromatic structure of 1.27 and the starting material was 
recovered. Though some peaks were observed but they might be due to allene gas 
photochemical reactions. As we failed to obtain any desired results (scheme 1.16) we 
now intended to use allyl alcohol, which was replaced with CH3CN as solvent (scheme 
1.17). 
 
1.5.2. Photochemistry of 1.27 using allyl alcohol.  
 
 
Reagents and conditions: i. , hv(125w UV lamp); 
Scheme 1.17: Photochemistry of 1.27 using allyl alcohol. 
11 
 
We tried to use allyl alcohol instead of allene gas 1.11 as allyl alcohol can be used as a 
solvent. The compound 1.27 was dissolved in 20 mL of allyl alcohol and a 125w U.V 
lamp was used as a light source. We changed the light source as in previous reaction 
with allene gas (scheme 1.16) with 16w U.V lamp, the reaction failed to give any 
desired result.  The mixture was subjected to photolysis (scheme 1.17). The reaction 
was monitored at 15 mins, 30 mins, 1 h, 2 h, 3 h and 5 h duration. The starting material 
completely reacted after 5 h. The compound was semi-solid viscous material and it was 
partially dissolvable in DCM and was not dissolvable in ether and ethyl acetate. The 
yield was very low and we could not get the desired compound 1.33. The H
1
-NMR 
showed the loss of aromatic character of the starting material and subsequently we 
failed to analyse the structure of the resulting product. 
We stopped working on the total synthesis of platensimycin 1.1 at this stage and moved 
on to another project, which is the total synthesis of kainic acid 2.1. 
 
 
 
 
 
 
 
 
  
 
 
 
 
CHAPTER TWO 
 
  
 
 
 
 
 
 
 
 
 
2. Introduction 
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2.1. Introduction to Kainoids 
2.1.1. Structure and Isolation 
α-(-)-Kainic acid 2.1 (figure 2.1) is the parent compound which consists of a pyrrolidine 
ring with stereo centers at the C-2, C-3 and C-4 positions, all with the S configurations. 
The simplest derivative of kainic acid 2.1 is allokainic acid 2.2 whose only structural 
difference is at the C-4 position where it possesses the opposite R stereochemistry. 
 
 
Figure 2.1: Kainic acid 2.1. 
 
Kainoid amino acids are an important class of pyrrolidine dicarboxylic acids, 
structurally derived from kainic acid 2.1. Structural and configurational differences are 
found in the C-4 substituent and give rise to a series of kainoid amino acids as shown in 
figure 2.2
8
. 
α-(-)-Kainic acid 2.1 is considered as the parent compound, as it was the first to be 
isolated in 1953 from the Japanese marine algae called ‘‘Kainin-sou’’ or ‘‘Makuri’’ 
(Digenea simplex)
9
 along with its C-4 epimer allokainic acid 2.2. Since then, kainic acid 
2.1 has been found in other organisms such as the algae Centrocerus calvulatum
10
 and 
the Corsican moss Alsidium helminthocorton.
11,12
 
Originally the structure was assigned as 3-carboxymethyl-4-isopropenylpyrrolidine-2-
carboxylic acid in a series of classical chemical degradations and syntheses of 
degradative products by Japanese chemists in 1955.
13-15
 Marimoto was the first, to 
assign the relative stereochemistry by chemical studies,
16
 
 
and this has been supported 
by X-ray analysis.
17,18
 
13 
 
                                      
  α-(-)-Kainic acid 2.1                       α-(+) –Allokainic acid 2.2                                   (-)-Domoic acid 2.3                                                  
                    
Isodomoic acid A (Z, E) 2.4                                                            Isodomoic acid C 2.6                                                      
Isodomoic acid B (E, E) 2.5 
                                 
Isodomoic acid D (Z, Z) 2.7                                Domoilactone A 2.10  
Isodomoic acid E (E, E) 2.8                           
Isodomoic acid F (E, Z)  2.9 
                   
Domoilactone B 2.11                                 Acromelic acid A 2.12                  Acromelic acid B 2.13
                                      
                           Acromelic acid C 2.14                                Acromelic acid D 2.15 
 
Figure 2.2: The kainoid amino acid family.8 
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2.1.2 Biological Properties 
 
Kainoid amino acids exhibit an array of biological properties, including 
anthelmintic,
17,18
 epileptogenic,
19
 insecticidal
20
 and neuroexcitatory activity.
21,22
 Among 
the kainates, kainic acid 2.1 exhibits an exceptional pharmacological profile, especially 
acting as an antiworming agent
20
. Recently, it has also been widely applied in 
neuroscience research as a neurodegenerative agent for modeling epilepsy
23,24
, 
Alzheimer’s disease25, and Parkinson’s disease.26 
Kainic acid 2.1 (Digenea simplex), has been used for its anthelmintic (anti-intestinal 
worm) properties for more than a thousand years.
27 
These properties are highly 
dependent on the relative configuration of the stereocenters, with the cis stereo-
chemistry at the C-3 and C-4 substituents appearing to be crucial to the anthelmintic 
function of all known stereoisomers. Since then, kainic acid 2.1, has been found to have 
an intense anthelmintic effect, about 10 times that of santonin.
17,18
 As  such  the C-4 
epimer allokainic acid 2.2 has been found to have only a weak anthelmintic effect.
28
 
The insecticidal properties of kainoids have long been utilised by the population of 
Yakushima Island, Japan. They used the extract of red algae Chondria armata, from 
which kainic acid 2.1 and domoic acid 2.3 have since been isolated, for its fly killing 
properties. Since then these compounds have shown to be potent insecticides towards 
the cockroach.
29
 The insecticidal activity is attributed to the nature of the side chain at 
the C-4 position of the pyrrolidine ring.
20
  
The predicated neuroexcitatory properties of the kainoid excitatory amino acids as 
conformationally restricted glutamic acid analogues have been well investigated.
30-33
 
The kainoids have a strong and selective affinity towards the kainite receptors, and have 
been shown to selectively block neuronal processes and are considerably valuable as 
tools in neurological studies. Their extremely potent activity, in both the vertebrate and 
invertebrate glutamergic systems,
34
 have been shown to be related to many 
neurodegenerative diseases. 
The pharmacological effects and patterns of neuronal degeneration,
34
 observed after 
injection of kainates have been shown to mimic the symptoms similar to those observed 
in patients suffering from neuronal diseases such as  Huntington’s chorea35 and 
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Epilepsy.
23
 Thus kainates have been used as tools in experimental models for central 
nervous system disorders, such as senile dementia.
30-33
 Although kainoids are very 
unlikely to become part of the treatment for neuronal diseases, as their extremely potent 
activity in both the invertebrate and vertebrate glutamergic system, leads to specific 
neuronal death in the brain.
34
 The information obtained from the biological models 
could provide new solutions in the treatment for neuronal diseases.  
After studying the biological properties of the many kainoids, the neuroexcitatory 
activity has been shown to be strongly attributed to the nature of the C-4 substituent. A 
double bond is essential to giving good excitatory activity and is also dependent upon 
the bonds conformation.
36-38
 For example in CPAA 2.16 (figure 2.3), which has no C-4 
substituent, shows no kainite-type selectivity. As previously mentioned the cis-
relationship between C-3 and C-4 appendages, plays a key role in excitatory activity. 
Kainic acid 2.1 shows enhanced activity compared to the C-4 epimer allokainic acid 2.2. 
Similarly, dihydrokainic acid 2.17 (figure 2.3),
37
 which has no π-electrons within its C-4 
substituent, exhibits no excitatory acitivity. The nature of the side chain at the C-4 
postion of the pyrrolidine ring also plays a crucial role in enhanced insecticidal 
activity.
20
 Compared to isodomoic acid C 2.6, domoic acid 2.3 is 23 times more active 
against the American cockroach.
29
 
 
 
Figure 2.3: CPAA 2.16 and dihydrokainic acid 2.17. 
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2.1.3 Biosynthesis: 
 
Wright suggested a biosynthetic pathway for domoic acid 2.3 and this route was likely 
to be a general pathway to all kainoids.
39
 The proline ring structure was generated by 
condensation of an activated glutamate derivative with an isoprenoid chain. Although 
both glutamic acid derivative 2.18 and geranyl pyrophosphate 2.19 are two different 
biogenetic units, both are entirely derived from acetate. Labelling experiments with     
[1-
13
C] acetate and [1,2-
13
C] acetate were used to provide evidence for condensation 
between glutamic acid 2.18 and a geranyl pyrophosphate 2.19 (scheme 2.1). Similarly, 
the biosynthetic pathway for kainic acid 2.1 was suggested by Wright, in which the 
proline ring system is generated by condensation of isopentenyl pyrophosphate (as an 
isoprenoid unit).
39
 
 
 
Scheme 2.1: Biosynthesis of domoic acid 2.3. 
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2.1.4. Previous Syntheses:  
 
To date, more than forty total syntheses and synthetic approaches to kainic acid 2.1 have 
been reported. The challenging cis-3,4 stereochemistry of kainoids, except for allokainic 
acid 2.2, have led to the development of several synthetic strategies. Further, the total 
synthesis of kainic acid 2.1, has been a synthetic challenge due to the three contiguous 
stereogenic centers in the pyrrolidine ring. As the biological acitivity of kainic acid is 
linked to the trans C-2/C-3 and cis C-3/C-4 stereochemistry, any synthesis needs to 
have efficient control of this relative stereochemistry. As such most of the syntheses to 
date start with enantiomerically pure starting material, for example, serine or glutamic 
acid. 
 
2.1.4.1. Oppolzer’s Synthesis
40 
 
The first enantioselective total synthesis of kainic acid 2.1 was completed by Wolfgang 
Oppolzer and Klaus Thirring in 1982.
40
 They used the commercially available (S)-
glutamic acid as the starting material.  
 
Reagents and conditions: i. Toluene, 130 
o
C, (75%); 
Scheme 2.2: Oppolzer’s synthesis of kainic acid 2.1. 
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The acid group was protected and the alkene was attached to the amido group by a 
reduction-oxidation sequence (scheme 2.2). The α,β-unsaturated ester was formed by 
successive selenation of the enolate, oxidation, and selenoxide elimination. This 1,6 
diene 2.22 underwent an ene- reaction in toluene at 130 
o
C to give the required cis C-
3/C-4 stereochemistry 2.23. Further deprotection gave rise to kainic acid 2.1. This was 
the first and shortest total synthesis of kainic acid 2.1 comprising only 6 steps with an 
overall yield of 5%. 
 
2.1.4.2. Knight’s Synthesis
41 
 
An enantiospecific route of kainic acid 2.1 was developed by Knight and co-workers in 
1987 using a stereocontrolled Ireland-Claisen rearrangement of a suitable azalactone 
2.25, to construct kainic acid’s 2.1 C-3/C-4 bond.40  
 
Reagents and conditions: i. (a) LDA, TBSCl, THF, -100 
o
C - 20 oC. (b) K2CO3, MeOH/H2O (55% over 2 
steps); 
Scheme 2.3: Knight’s synthesis of kainic acid 2.1. 
 
Azalactone 2.25 was formed by utilising the starting material ʟ-aspartic acid 2.24. Here, 
the actual rearrangement occurred as the reaction mixture was warmed to ambient 
temperature. Hydrolysis of the resulting silyl ester gave the desired 
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pyrrolidinecarboxylic acid 2.26 in 2 steps (scheme 2.3). Arndt-Eistert homologation of 
the acid 2.26 followed by oxidation furnished kainic acid 2.1.  
 
2.1.4.3. Baldwin’s Synthesis
42 
 
Baldwin and Li reported the application of a homolysis and β-elimination sequence to 
the enantioselective synthesis of kainic acid 2.1 and allokainic acid 2.2 in the year 1987. 
They reported two methods, one of which pertains to the cyclisation of the iodide 2.28 
(scheme 2.4). The key iodide 2.28 was obtained in 54% yield from ʟ-threonine methyl 
ester in four steps
35
. The cobaloxime mediated cyclisation of 2.28 afforded a mixture of 
the separable isomers 2.29 and 2.30 with the syn-pyrrolidine 2.29 predominating (5:3). 
These isomers on deprotection and oxidation gave kainic acid 2.1 and allokainic acid 
2.2 respectively. The Co(I), in addition to the formation of pyrrolidine ring, introduces a 
double bond at the C-4 side chain via a dehydrocobaltation process.
43 
 
 
Reagents and conditions: i. Cobaloxime(I); 
Scheme 2.4: Baldwin’s synthesis of kainic acid 2.1 and allokainic acid 2.2. 
 
2.1.4.4. Takano’s Synthesis 
 
Takano’s interest in kainic acid 2.1 has been well documented, with four 
enantioselective syntheses to his credit.
44,48,50,51
 The first synthesis reported in 1988 
involved an intramolecular 1,3-dipolar cyclisation of aziridine ester 2.31. Thermolysis 
of ester 2.31 in xylene and diastereoselective intramolecular cycloaddition gave the 
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pyrrolidine lactone 2.33 in all-cis configuration (scheme 2.5).
44
 The stereochemical 
outcome was explained by the author as a result of the ylide adopting exo-conformation 
2.32 for the active intermediate in which the bulky benzyloxymethyl group assumes an 
equatorial orientation with respect to the forming δ-lactone moiety. Hydrolysis of the 
lactone moiety 2.33 followed by sequential oxidative treatment (CrO3 and HIO4) 
introduced the C-3 and C-4 appendages in kainic acid 2.1. The ester at the C-2 position 
required further epimerisation to afford the required kainic acid 2.1. 
 
 
Reagents and conditions: i. xylene, 305-310 
o
C, sealed tube (70%); 
Scheme 2.5: Takano’s synthesis of kainic acid 2.1. 
 
In the same year 1988, Takano
45
 proposed another enantioselective synthesis of kainic 
acid 2.1 using an intramolecular-hetero Diels-Alder reaction to construct the cis-C-3/C-
4 ring junction of kainic acid 2.1. The diene 2.35, formed on reaction of 2.34 with 
Meldrum’s acid,46  accompanied by intramolecular [4+2] cycloaddition to give 2.36 as a 
single diastereomer shown below (scheme 1.6). The stereochemical outcome was 
presumed to be a result of the sp
2
-planar like configuration of the carbamate nitrogen, 
which allows efficient [4π + 2π] overlap of only the endo-conformer. The subsequent 
opening of lactone 2.36 generated a suitable precursor for the formation of kainic acid 
2.1(scheme 2.6).  
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Reagents and conditions: i. Meldrum’s acid, EDTA; 
Scheme 2.6: Takano’s synthesis of kainic acid 2.1. 
 
The overall yield of kainic acid 2.1 from the precursor obtained from lactone 2.36 was 
22%. 
Another new enantiospecific route to kainic acid 2.1 via the intramolecular Pauson-
Khand reaction was proposed by Takano (scheme 2.7) in the year 1992.
47
 The treatment 
of 2.37 with Co2(CO)8 and then NMO, furnished a bicyclic enone 2.38 as an inseparable 
mixture of diastereoisomers in 85% yield. The mixture further undergoes a 
stereoselective reduction of the alkene and removal of the THP group, to furnish the 
desired adduct 2.39, as major product in 60% yield. The adduct 2.39 undergoes further 
modifications in 9 steps to give kainic acid 2.1. 
 
 
Reagents and conditions: i. (a) Co2(CO)8 (1.2 eq.), benzene, rt.  (b) NMO (6 eq.), DCM, 0 
o
C (85% over 2 
steps); ii. (a) LiAlH4, CuI, HMPA-THF (1:4), -78 
o
C  (b) p-TSA, MeOH, rt, then separation by SiO2 
column; 
Scheme 2.7: Takano’s synthesis of kainic acid 2.1. 
 
Takano, starting from ʟ-Serine 2.40 proposed another novel asymmetric synthesis of 
kainic acid 2.1 and allokainic acid 2.2 using protodesilylation step
48
 in the year 1993. 
22 
 
α,β-Unsaturated ester 2.41 was prepared in four steps starting from ʟ-Serine 2.40. 
Treatment of 2.41 with tributyltin hydride in the presence of catalytic amount of AIBN 
in boiling benzene resulted in a highly diastereoselective radical cyclisation to give 
exclusively the substituted pyrrolidine 2.42. The compound 2.42 was found to be a 
useful intermediate and underwent crucial protodesilylation step using various 
substrates which were prepared from 2.42. Pyrrolidine 2.42 undergoes further 
modifications to give compounds 2.43 and 2.45 (scheme 2.8). Two-step oxidation of the 
primary alcohol of 2.43, followed by BF3·Et2O-mediated protodesilylation proceeded 
with opposite diastereoselectivity to give the 3,4-cis-pyrrolidine 2.44, which on further 
treatment in two steps gave kainic acid 2.1. Treatment of 2.45 with BF3·Et2O in 
methylene chloride, directed an intramolecular protodesilylation with complete 
diastereoselectivity to give 3,4-trans-pyrrolidine 2.46. The compound 2.46 in another 2 
steps gives allokainic acid 2.2. 
 
Reagents and conditions:  i. Bu3SnH, AIBN (catyalyst), benzene, reflux; ii. (a) DIBAL, DCM, -78 
o
C. (b) 
t
BuCOCl, Et3N, DMAP, DCM. (c) 46% HF, MeCN; iii. (a) (COCl)2, DMSO, DCM, -60 
o
C then Et3N. (b) 
NaClO2, NaHPO4, 2-methylbut-2-ene, 
t
BuOH-H2O (4:1); iv. (a) 10 eq. BF3·Et2O, DCM. (b) CH2N2, Et2O; 
v. 5% KOH in MeOH; vi. (a) 3 eq. BF3·Et2O, DCM. (b) CH2N2, Et2O. (c) 46% HF, MeCN; vii. (a) 
H2CrO4, acetone. (b) CH2N2, Et2O; 
Scheme 2.8: Takano’s synthesis of kainic acid 2.1 and allokainic acid 2.2. 
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2.1.4.5. Spalluto’s Synthesis
49 
 
Based on a one-pot tandem Michael reaction methodology, Spalluto and co-workers in 
1992 envisaged a new enantioselective route to the kainoid family (scheme 2.9).  The 
pyrrolidine 2.49 which could give the desired kainic acid 2.1 was obtained by simply 
stirring equimolar quantities of 2.47 and 2.48 at room temperature in ethanol for 15 h. 
The electrophilic component 2.48 was obtained from 2.50 in situ, where 2.47 acts both 
as donor-acceptor partner as well as basic catalyst for generating 2.48. Here nitro group 
plays a noteworthy role in crucial stereo- and   regio-chemical control. 
 
 
Reagents and conditions: i. Ethanol, rt, 15 h; 
Scheme 2.9: Spalluto’s synthesis of kainic acid 2.1. 
 
 
2.1.4.6. Yoo’s Synthesis
50,51 
 
Another synthetic route for kainic acid 2.1 has been developed based on the Pauson-
Khand reaction as the key step, was developed by Yoo
50
 in 1993. The optically active 
vinylacetylene 2.51 was subjected to Pauson-Khand conditions which yielded the trans-
bicyclic enone as an inseparable mixture of diastereomers (2.52 + 2.53) in 95% yield 
(scheme 2.10). The diastereomer 2.52 underwent further modifications and was then 
converted to kainic acid 2.1 in overall 5 steps. 
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Reagents and conditions: i. (a) Co2(CO)8, DCM. (b) TMANO (95% over 2 steps, (2.52: 2.53) = (1.7:1)); 
Scheme 2.10: Yoo’s synthesis of kainic acid 2.1. 
 
The precursor 2.51 used in the Pauson-Khand reaction (scheme 2.10) was further 
modified by Yoo
51
 in 1994, to increase the diastereoselectivity by employing a rigid 
oxazolidinone moiety 2.54. Under the similar conditions (scheme 2.10), the 
oxazolidinone 2.54 gave a single isomer 2.55 in 93% yield (scheme 2.11). 
 
 
Reagents and conditions: i. Co2(CO)8, DCM;  ii. TMANO (93% over 2 steps); 
Scheme 2.11: Yoo’s synthesis of kainic acid 2.1. 
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2.1.4.7. Monn’s Synthesis
52
 
 
 
Reagents and conditions: i. 2-cyclopentenone, Et3N, CH3CN, rt; ii. (a) Bu3SnH, AIBN, toluene, reflux.  
(b) HCl, H2O, rt. (c) Benzylchloroformate, NaOH, 5 
o
C, 64%; iii. (a) MeLi, TiCl4, DCM, Et2O. (b) BF3-
Et2O, DCM, reflux; iv. RuO2, NaIO4, CCl4, CH3CN, H2O, rt; 
Scheme 2.12: Monn’s synthesis of kainic acid 2.1. 
 
A stereocontrolled thiazolium ylide approach to kainic acid 2.1 was reported by Monn 
and Valli in 1994. They successfully prepared a separable mixture of tetracycles 2.57 
and 2.58 on a large scale (up to 1.5 mol) in excellent (70-80%) isolated yields (scheme 
2.12). Reductive cleavage of the thiazoline C-S bond with Bu3SnH followed by in situ 
hydrolysis of the resulting hemiaminal followed by protection of nitrogen as its benzyl 
carbamate afforded 2.59 in 64% yield. In further two steps they could successfully 
afford the formation of 2.61 which led to the formation of kainic acid 2.1 in 8% overall 
yield from 2-cyclopentenone.
52 
 
 
2.1.4.8. Hanessian’s Synthesis
53 
 
A trimethylstannyl-mediated radical carboxylization approach was proposed by 
Hanessian in 1996 for the stereoselective synthesis of kainic acid 2.1 and allokainic acid 
2.2. The synthesis commenced with ʟ-serine 2.62, which was transformed into 
compound 2.63 and 2.64 in 6 steps for each compound (scheme 2.13).  
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Reagents and conditions: i. Me3SnCl, slow addn. of NaCNBH3, 
t
BuOH, reflux, AIBN; 
Scheme 2.13: Hanessian’s synthesis of kainic acid 2.1 and allokainic acid 2.2. 
 
The diene 2.63 was treated with trimethyltin hydride generated under Stork’s 
conditions
54
; a mixture of stannylated compounds was obtained, favouring the cis 
stereochemistry at the C3-C4 centers in a ratio of 2.8:1. However, a slow addition of 
sodium cyanoborohydride over a period of 1h to a refluxing solution containing the 
compound 2.63 and trimethyltin chloride afforded the cyclised product 2.65 and its C4 
isomer as an inseparable mixture in 88% yield without compromising the cis/trans ratio. 
The mixture was then treated with CAN in methanol to oxidatively cleave the C-Sn 
bond in order to obtain the destannylation of 2.65.  The resultant dialkyl acetal
53
 formed
 
was further transformed into kainic acid 2.1 10 steps in 2% overall yields. Under the 
similar conditions, substrate 2.66 was converted into allokainic acid 2.2 in 3% overall 
yield. 
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2.1.4.9 Bachi’s Synthesis
55 
 
 
Reagents and conditions: i. EtSH, AIBN, toluene, 60 
o
C, 5 h; ii. MeOK, THF/MeOH/methyl formate 
(40:2:1), rt, 3 h, neutralized with AcOH; iii. MeOK and methyl formate in MeOH/THF; 
Scheme 2.14: Bachi’s synthesis of kainic acid 2.1. 
 
The stereocontrolled synthesis of kainic acid 2.1 by sulfur radical mediated cyclisation 
was reported by Mario D. Bachi in 1997. The highly functionalised monothioformimide 
2.67 was formed in three steps.
55
 The radical cyclisation of 2.67, mediated by               
n-Bu3SnH/AIBN gave the tetrasubstituted pyrrolidine 2.70, which on desilylation gave 
the enantiomerically pure key compound 2.71, in 73% overall yield starting from 2.67. 
The compound 2.71 was converted to the rather stable sulfone 2.72 in further two steps 
(scheme 2.14). Treatment of the sulfone-tethered acetic acid ester 2.72 with potassium 
methoxide and methyl formate in MeOH/THF gave the desired cyclic α-chloromethyl-
sulfone 2.73. The compound 2.70 upon further treatment gave kainic acid 2.1. 
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2.1.4.10. Ogasawara’s Synthesis  
 
An intramolecular ene-reaction was utilised in the synthesis of kainic acid 2.1 by Kunio 
Ogasawara
56 
in the year 1997.  
 
 
Reagents and conditions: i. PhOPh, reflux, 60 min, 90% (>99% ee); 
Scheme 2.15: Ogasawara’s synthesis of kainic acid 2.1. 
 
The compounds 2.76 and 2.77 were formed starting from the enantiomers of optically 
pure ketodicyclopentadiene 2.74 and 2.75. These underwent a concurrent one-pot retro-
Diels Alder reaction and intramolecular ene reaction of the transient 1,6 diene 2.78, to 
afford an all-cis bicyclo product 2.79  in 90% yield and >99% ee (scheme 2.15). The 
bicyclic pyrrolidine 2.79 gave the core to the total synthesis of kainic acid 2.1. 
Another route proposed by Ogasawara in the year 2000 involved a concurrent Chugaev 
syn-elimination
57
 and intramolecular ene reaction as the key step in the synthesis of 
kainic acid 2.1 (scheme 2.16).  
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Reagents and conditions: i. NaHCO3, PhOPh, reflux, 45 min, (72%);  
Scheme 2.16: Ogasawara’s synthesis of kainic acid 2.1. 
 
The key xanthate ester 2.81 was prepared from the enantiopure starting material cis-4-
carbobenzoxyamino-2-cyclopentenol 2.80 in 6 steps. Thermolysis of xanthate ester 2.81 
in diphenyl ether  in the presence of sodium hydrogen carbonate gave the tricyclic 
product 2.83, bearing the trisubstituted pyrrolidine framework required for the kainic 
acid 2.1 in 72% yield as a single diastereomer. This was formed, presumably, via the 
transient exo-1,6-diene intermediate 2.82.  
 
 
2.1.4.11. Naito’s Synthesis
58 
 
Takeaki Naito in the year 1997, proposed an enantioselective synthesis of kainic acid 
2.1 via a route involving a sulfur radical addition-cyclisation-elimination reaction 
(scheme 2.17). The requisite diene 2.86 was prepared through a Mitsunobu reaction of 
the (S)-vinylglycinol 2.84 with the hydroxyl sulphide 2.85. The sulfur radical addition-
cyclisation-elimination reaction of 2.86, in the presence of thiophenol and AIBN in 
boiling benzene under nitrogen gave the 3,4-cis-(2.87) and 3,4-trans-(2.88) in 41 and 
53% yields respectively. The resulting carbon radical undergoes 5-exo-trig cyclisation
53
. 
The isomers 2.87 and 2.88 were potential synthetic compounds for the total synthesis of 
kainic acid 2.1 and allokainic acid 2.2 respectively. 
30 
 
 
Reagents and conditions: i. DEAD, Ph3P, 68%, ii. PhSH, AIBN, C6H6; 
Scheme 2.17: Naito’s synthesis of kainic acid 2.1 and allokainic acid 2.2. 
 
 
2.1.4.12. Rubio’s Synthesis
59 
 
Rubio in the year 1998 developed an approach to the synthesis of kainic acid 2.1 based 
on the stereocontrolled functionalization of N-Boc protected pyroglutamate ester 2.89 
(scheme 2.18). BF3·OEt2 mediated aldol condensation of the pyroglutamate lactam 
enolate using LiHMDS in acetone at -78 
o
C generated a mixture of cis and trans aldols 
(1:4 ratio), which were inseparable. To obtain the trans aldol 2.90, it was necessary for 
the deprotection of the nitrogen. Subsequent reprotection of nitrogen under standard 
conditions gave 2.90 in 45% yield as a single isomer. 2.90 underwent reduction of 
ketone group, followed by generation of double bond to give Michael acceptor 2.91 in 
two steps. The addition of diethyl malonate anion to 2.91 furnished the Michael adduct 
2.92 in 65% yield as a single diastereomer. Change of the stereochemistry at the C-3 
position was achieved by the formation of double bond and subsequent hydrogenation 
of the double bond using PtO2 in ethanol, which gave an all-cis prolinate 2.93 in two 
steps.
59
 This was followed by decarboxylation, epimerization of the C-2 centre and 
deprotection finally gave kainic acid 2.1 in another 10 steps.      
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Reagents and conditions: i. LiHMDS/Acetone, Et2OBF3; ii. TFA/DCM, Separation; iii. (Boc)2O/DMAP, 
(45% over 3 steps); iv. NaH/THF, CH2(CO2Et)2 , 65%; 
 
Scheme 2.18: Rubio’s synthesis of kainic acid 2.1. 
 
 
 
2.1.4.13. Cossy’s Synthesis
60 
 
Cossy’s approach to the cis-C-3/C-4 geometry of kainic acid 2.1 in the year 1999 was 
accomplished by using a ketyl radical cyclisation on an ene carbamate (scheme 2.19).  
 
 
Reagents and conditions: i. SmI2, HMPA, 
t
BuOH, THF, (55%); 
Scheme 2.19: Cossy’s synthesis of kainic acid 2.1. 
 
Ketone 2.95 was synthesised from the enone 2.94 in 6 steps. This compound underwent 
a 5-exo-trig radical cyclisation using SmI2, which gave the bicyclic pyrrolidine alcohol 
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2.96 in 55% yield. The pyrrolidine alcohol 2.96 underwent dehydration, followed by 
oxidative cleavage and reduction to give alkene 2.97, having the core structure of kainic 
acid 2.1, which was subsequently converted to 2.1 in 4 steps. 
 
 
 
2.1.4.14. Montgomery’s Synthesis
61 
 
In the year 1999, Montgomery carried out a short and efficient total synthesis of kainic 
acid 2.1 and formal synthesis of allokainic acid 2.2, using a highly stereoselective 
approach, involving complementary allene and alkyne cyclisations.  
 
 
Reagents and conditions: i. (a) (COCl)2, DMSO, Et3N, DCM, -78 
o
C. (b) 2.102, DMAP, DCM, -20 -     
25 
o
C,   62%, 2 steps; ii. MeLi/ZnCl2, Ni(COD)2 (10 mol%), Ti(O 
i
pr)4, 57% (98:2 diastereomeric ratio); 
 
Scheme 2.20: Montgomery’s synthesis of kainic acid 2.1. 
 
Oxazolidinone 2.98 was N-propargylated with propargyl bromide followed by 
homologation to afford allene 2.99, which in turn was subjected to Swern oxidation
62
 
followed by Wittig olefination with a triphenyl phosphonium ylide 2.102 gave the 
cyclization substrate 2.100. The substrate 2.100 was treated with MeLi/ZnCl2 in the 
presence of Ni(COD)2 and Ti(O 
i
pr)4 directly afforded the cyclised compound 2.101 in a 
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57% yield with diastereomeric ratio 98:2 favouring the stereochemistry found in kainic 
acid 2.1 (scheme 2.20).  
In the approach to a formal synthesis of allokainic acid 2.2, ᴅ-serine methyl ester was 
efficiently converted to the cyclisation substrate 2.103. This was followed by cyclisation 
of 2.103 with commercial trimethylaluminum and Ni(COD)2 (10 mol %) in THF 
afforded a 73% yield of 2.104 with a favourable desired trans stereochemistry (scheme 
2.21). The compound 2.104 was further reduced to afford 2.105 which could give the 
required allokainic acid 2.2.   
 
 
Reagents and conditions: i. (a) AlMe3 (3 eq), 10 mol % Ni(COD)2, THF, 0 
o
C, 40 min, 73% (97:3 
diastereoisomeric ratio). (b) HF·Pyr, THF, 0 oC-  25 oC, 24 h, 86%; then  methylchloroformate (3 eq), 
pyridine, DCM, 0
 o
C - 25 
o
C, 3 h, 83%; 
Scheme 2.21: Montgomery’s synthesis of allokainic acid 2.2. 
 
2.1.4.15. Clayden’s Synthesis
63 
 
Clayden in the year 2000 described the dearomatising cyclisation of a lithiated N-benzyl 
p-anisamide in the synthesis of kainic acid 2.1. The cyclisation substrate 2.107 was 
prepared starting from acylation of cumylamine 2.106 with p-anisoyl chloride 2.111, 
followed by benzylation of the secondary amine. Amide 2.107 when lithiated with 
t
BuLi in the presence of HMPA, formed the cyclisation product 2.109, which on 
protonation gave the dienyl ether 2.110 in good yield as a single regioisomer. Here we 
can see the introduction of three asymmetric centres in one synthetic operation from 
compound 2.108 (scheme 2.22). 
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Reagents and conditions: i. (a) p-anisoyl chloride (2.111), Et3N, DCM, (b) NaH, DMF, BnBr, 18 h, 82%; 
ii. 
t
BuLi (2 eq.), HMPA (12 eq.), THF, -40 
o
C, 60 h; iii. NH4Cl; 
Scheme 2.22: Clayden’s synthesis of kainic acid 2.1. 
 
 
2.1.4.16. Ganem’s Syntheses
64 
 
Ganem produced short and efficient total syntheses of kainic acid 2.1 in 2001, using an 
enantioselective, metal-promoted ene cyclisation.  
 
 
Reagents and conditions: i. (2.113), Mg(ClO4)2, DCM (72%), (2.114: 2.115) = (>20:1); ii. a) Cp2ZrHCl, 
THF,  b) TMSCN, DCM (75% over 2 steps);  
Scheme 2.23: Ganem’s synthesis of kainic acid 2.1. 
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The diene 2.112 was cyclised in the presence of Mg(ClO4)2 to generate the desired cis-
isomer 2.114 predominantly. This high diastereoselectivity was attributed to the ligand 
2.113.  Lactam 2.114 on reaction with Schwartz’s reagent (Cp2ZrHCl, 1.5 equiv in 
THF) generated an intermediate imine 2.116, which was treated with 
cyanotrimethylsilane (TMSCN) in DCM to afford an all-cis nitrile 2.117 (scheme 2.23). 
The nitrile 2.117 underwent hydrolysis of both the ester and the nitrile groups, followed 
by epimerization of the C-2 substituent to give kainic acid 2.1 in a good overall yield of 
20%.  
 
 
2.1.4.17. Trost’s Syntheses
65
 
 
 
Reagents and conditions: i. 10%[CpRu(CH3CN)3]PF6, 2% H2O/acetone, 40 
o
C, malonic acid (1 eq.),             
3 h, 80% yield, 96% ee; ii. 20% [Ir(cod)Py(PCy3)]PF6, H2 (2000 psi ); 
Scheme 2.24: Trost’s synthesis of kainic acid 2.1. 
 
A novel route for the asymmetric total syntheses of kainic acid 2.1 was reported by the 
Trost group, where the key concept derived from a ruthenium-catalysed 
cycloisomerisation of a tethered alkyne-propargyl alcohol 2.118 to form a cyclic 3-acyl-
4-vinyl pyrrolidine 2.119. Silicon moiety was introduced by a novel 1,6 addition on 
compound 2.119 followed by olefin isomerisation and removal of benzyl group to form 
alcohol 2.120. The stereochemistry of 2.121 was attained by the asymmetric reduction 
occurred with Crabtree’s catalyst66 [Ir(cod)Py(PCy3)]PF6 on alcohol 2.120. Reduction of 
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ketone followed by oxidation of C-2 and C-3 groups of 2.121 would give kainic acid 2.1 
in 4 subsequent steps. 
 
 
2.1.4.18. Anderson’s Synthesis
67 
 
 
Reagents and conditions i. LDA, 78%; ii.  I2, 85%; iii. TFA, KOH, 86%; 
Scheme 2.25: Anderson’s synthesis of kainic acid 2.1. 
 
Anderson’s key stereochemical determining step in the route to the kainoid skeleton was 
an aza-[2,3]-Wittig sigmatropic rearrangement (scheme 2.25). Compound 2.123 was 
prepared from the commercially available 3-butyne-1-ol 2.122.  The aza-[2,3]-Wittig 
rearrangement was induced using LDA to give the unnatural amino acid derivative 
2.124 in a 78% yield. This underwent protodesilylation to form 2.125. Iodolactonization 
of 2.125 with I2 in DME/H2O gave 2.126 as the major diastereoisomer. Deprotection of 
the amine and subsequent base-induced ring opening of the lactone followed by a 5-exo-
tet cyclisation gave the proline skeleton 2.127 seen in kainic acid 2.1. The synthesis was 
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completed in a further six steps to give the kainic acid 2.1 in overall 18 steps starting 
from 3-butyne-1-ol 2.122. 
 
 
2.1.4.19. Hoppe’s Synthesis
68 
 
In the year 2004, Hoppe reported an enantioselective synthesis of kainic acid 2.1, based 
on a (-)-sparteine 2.131 mediated asymmetric deprotonation of an intermediate 
carbamate 2.129. N-benzyl-protected ᴅ-serine methyl ester hydrochloride 2.128 is 
converted to the key precursor carbamate 2.129.
62  
 
 
Reagents and conditions: i. (a) n-BuLi, (-)-Sparteine (2.2 eq.), toluene, -78 
o
C, 1 h. (b) MeOH;                
Cb = C(O)Ni-Pr2; 
Scheme 2.26: Hoppe’s synthesis of kainic acid 2.1. 
 
Intramolecular anti SNʹ SEʹ cycloalkylation of (E,E)-carbamate 2.129, commenced with 
α-deprotonation by means of n-BuLi/(-)-sparteine at -78 oC in toluene to give the 
pyrrolidine 2.130 as the major diastereomer (scheme 2.26). The C3-C4 cis pyrrolidine 
2.130 would undergo further modifications to form kainic acid 2.1 in 7 subsequent 
steps. 
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2.1.4.20. Lautens’s Synthesis
69 
 
Lauten in the year 2005, reported a concise and enantioselective synthesis of kainic acid 
2.1 in 13 steps with an overall yield of 15%. The pyrrolidine 2.134 kainoid precursor 
was prepared by MgI2-mediated ring expansion of N, N-diphenylmethylene-cyclopropyl 
amide 2.133 in the presence of a chiral sulfinimine 2.132 with the required C2/C3 trans 
stereochemistry (scheme 2.27). Hydroboration of the pyrrolidine 2.134 from the least 
hindered face using 9-BBN, followed by standard oxidative workup, afforded the 
alcohol 2.135 as a single diastereomer. This alcohol 2.135 provided the required 
stereochemistry for an en-route synthesis of kainic acid 2.1. 
 
 
Reagents and conditions: i. MgI2, THF (78%); ii. 9-BBN, THF, 50 
o
C then NaOH, H2O2 (91%); 
Scheme 2.27: Lautens’s synthesis of kainic acid 2.1. 
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2.1.4.21. Fukuyama’s synthesis  
 
To date Fukuyama has produced four total synthesis of kainic acid 2.1. The first total 
synthesis in the year 2005, involved regio- and stereoselective lithiation of the 
pyrrolidine ring 2.139 with the (+)-sparteine derivative 2.140 (scheme 2.28).
70
 
Cycloadduct 2.138 is formed by the 1,3-dipolar cycloaddition of the chiral butenolide 
2.136 and azomethine ylide formed from 2.137 with high diastereoselectivity (20:1). 
The cycloadduct 2.138 is converted to the MOM protected pyrrolidine derivative 2.139 
in 8 subsequent steps. Compound 2.139 on treatment with (+)-sparteine and s-BuLi at    
-78 
o
C gave the trisubstituted pyrrolidine derivative as an inseparable mixture of regio- 
and diastereoisomers 2.141 and 2.142.The undesired isomer was epimerised and the 
MOM group removed. This allowed separation of the regioisomers, with the desired 
isomer as major product in 2 steps in 63% yield.  
 
 
Reagents and conditions: i. 2.137, TFA(10 mol %), DCM, 83%; ii. 2.140, s-BuLi, THF, CO2 (g), -78 
o
C; 
Scheme 2.28: Fukuyama’s synthesis of kainic acid 2.1. 
 
In the year 2007, Fukuyama reported another total synthesis of kainic acid 2.1 by Ring-
Closing Metathesis followed by an intramolecular Michael addition.
71
 The metathesis of 
compound 2.144 was conducted using the Hoveyda-Grubbs’ second-generation 
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catalyst
72
 2.145. The use of 5 mol % of the catalyst in DCM at 80 
o
C afforded the 
desired lactone 2.146 in 98% yield.  
 
 
Reagents and conditions: i. Hoveyda-Grubbs’ 2nd Generation Catalyst 2.145 (5 mol %), DCM, 80 oC, 24 
h, 98%; ii. KHMDS, toluene, -78 
o
C, 89 %, (2.147: 2.148 = 71:29); 
Scheme 2.29: Fukuyama’s synthesis of kainic acid 2.1.  
 
The crucial Michael addition was achieved by treatment of 2.146 with KHMDS in 
toluene at -78 
o
C to provide a mixture of the desired pyrrolidine derivative 2.147 and its 
C-2 epimer 2.148 in a 71:29 ratio (scheme 2.29). The pyrrolidine derivative 2.147 
underwent further modification to form kainic acid 2.1 in 6 subsequent steps. 
Similar to the above, another total synthesis of kainic acid 2.1 starting from the 
commercially available azetidinone 2.149 was described by Fukuyama
73
 in the year 
2008. Compound 2.151 was prepared through the Reformatsky-type
74
 reaction from 
2.149 using t-butyl bromozincacetate 2.150. The desired β-amino-δ-lactone 2.152 was 
prepared in 7 subsequent steps from 2.151. 
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Reagents and conditions: i. 2.150, THF, 0
 o
C - rt, 12 h, 93%; ii. (a) LiHMDS, CbzCl, DMF, -60 
o
C - rt, 20 
min, (b) LiHMDS, -60 
o
C, 20 min, 94%, 2.152: C2-epimer = 92:8; 
Scheme 2.30: Fukuyama’s synthesis of kainic acid 2.1. 
 
Cyclisation of 2.152 took place smoothly to afford a diasteromeric mixture of the 
desired pyrrolidine derivative 2.153 and its C-2 epimer in 92:8 ratio (scheme 2.30). The 
pyrrolidine derivative 2.153 was converted to kainic acid 2.1 in a further 5 steps in 14% 
overall yield. 
 
 
Reagents and conditions: i. LiHMDS, THF, -78 
o
C, BrCH2CO2
t
Bu, -78
 o
C, 82%; ii. Zn, AcOH, EtOH, 
0
o
C - rt.; iii. DEPC, Et3N, DCM, rt. 60% (2 steps); 
Scheme 2.31: Fukuyama’s synthesis of kainic acid 2.1. 
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The most recent synthesis by Fukuyama was a practical stereoselective synthesis 
efficiently prepared from (+)-carvone 2.154
75
 in the year 2011. Iodolactone 2.155 was 
prepared in six steps starting from carvone 2.154. Having developed iodolactone 2.155, 
followed by addition of tert-butyl bromoacetate at -78 
o
C furnished ester 2.156 in 82% 
yield. Carboxylic acid 2.157 was prepared by the reductive ring-opening reaction of the 
iodolactone moiety in 2.156 by treatment with Zn dust in the presence of acetic acid 
(scheme 2.31). The carboxylic acid 2.157 upon treatment with DEPC
76
 and 
triethylamine at ambient temperature, underwent cyclization to afford the desired cis-
substituted lactam 2.158, which was further elaborated to give kainic acid 2.1 in 5 steps. 
Starting from 100 g of carvone 2.154 Fukuyama could get 14.6 g of kainic acid 2.1 in 
10.3% overall yield. 
 
2.1.4.22. Cohen’s Synthesis
77 
 
Cohen reported the total synthesis of kainic acid 2.1 in the year 2007, which features a 
Pd-catalyzed Zn mediated cyclisation that proceeds with complete diastereoselectivity. 
Both cyclisation substrates 2.159 and 2.160 were prepared from the commercially 
available ᴅ-serine methyl ester hydrochloride.  
 
Reagents and conditions: i. (a) Pd
(0)
, ZnEt2.   (b) I2; 
Scheme 2.32: Cohen’s synthesis of kainic acid 2.1. 
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The Pd-catalyzed Zn-ene cyclization of 2.159 provided pyrrolidine 2.161 in a 55% yield 
as a single diastereomer (scheme 2.32). The cyclisation of diene 2.160 provided, 
pyrrolidine 2.161 in 91% yield as a single diastereomer. Pyrrolidine 2.161 undergoes 
further modifications in 5 steps to give kainic acid 2.1.  
 
 
2.1.4.23. Jung’s Synthesis
78 
 
K. W. Jung in the year 1997, reported a novel approach to the total synthesis of            
(-)-α-kainic acid 2.1 and (+)-α-allokainic acid 2.2, wherein a regio- and stereoselective 
C-H insertion reaction was utilized to prepare the γ-lactam 2.164 as an intermediate.  
 
 
Reagents and conditions: i. Rh2(OAc)4, DCM, 92%; ii. Ac2O, NaH, THF, 98%; iii. (a) Dowex 50W-8X. 
(b) TBDMSCl, DMAP, TEA, DCM. (c) Boc2O, TEA, DCM, 70%; 
Scheme 2.33: Jung’s synthesis of allokainic acid 2.2. 
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The C-H insertion precursor 2.163 was prepared from ʟ-glutamic acid 2.162 over 6 
steps. A Rh(II) catalyzed intramolecular C-H insertion of diazo compound 2.163 then 
gave the desired trans- γ-lactam 2.164 as a single isomer in 92% yield with excellent 
regio- and stereoselectivity. Acetylation of the phenylsulfone of 2.164 was carried out 
efficiently, using Ac2O and NaH in THF to give acetyl compound 2.165 (scheme 2.33). 
The trans intermediate 2.166, was prepared from acetyl compound 2.165 in 4 steps. 
After the successful isolation of trans-C6, C7 conformational product 2.166, the 
acetonide in compound 2.166 was unmasked, and subsequent Boc protection furnished 
trisubstituted pyrrolidone 2.167, which would give allokainic acid 2.2 in further 6 steps. 
 
 
Reagents and conditions: i. TBSOTf, TEA, DCM, 99%; ii. Na/Hg, THF/MeOH, 98%; iii. (a) m-CPBA, 
DCM, 65%. (b) NaOMe, MeOH, -78 
o
C, 85%; 
Scheme 2.34: Jung’s synthesis of kainic acid 2.1. 
 
Utilizing compound 2.164, a new strategy for the stereoselective installation of the cis-
C3, C4 relationship to achieve the synthesis of kainic acid 2.1 was proposed. The ester 
compound 2.168 was formed in 9 steps from 2.164 (scheme 2.34). Silylation of 
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cyclohexenone 2.168 using TBSOTf in the presence of TEA gave a mixture of two 
isomers 2.169 and 2.170 in a ratio of 2:1. The mixture of both the isomers were 
subjected to reduction conditions using Na/Hg at -20 
o
C to provide only one 
diastereomer in 98% yield. Here during the dephenylsulfonylation, deprotection of 
TBDMS group took place to yield cyclohexenone 2.171. The cyclohexenone 2.171 
underwent a Baeyer-Villiger oxidation, followed by a ring opening of the enol lactone 
formed using NaOMe at -78 
o
C in two steps to give the aldehyde ester compound 2.172. 
This on further modification gives kainic acid 2.1 as the final product in 7 steps. 
 
 
2.1.4.24. Suzuki’s Synthesis
79 
 
An asymmetric synthesis of (±)-kainic acid 2.1 using a planar chiral amide as a chiral 
building block was reported by Masaki Suzuki. The requisite amide (S)- 2.173 was 
prepared by a previously developed method,
80
 which underwent a subsequent Cope 
rearrangement in the presence of Pd(II) to yield (3S, 4S)- 2.174 as the sole product in 
87% yield. Diene 2.174 underwent deprotection, reprotection and oxidation of double 
bond in 4 steps to give TBS protected alcohol 2.175.  
 
 
Reagents and conditions: i. cat. PdCl2(PhCN)2, DCM, rt, 87%; ii. s-BuLi, 2.178, Et2O, -78 
o
C then 
ClCOOMe, -78 
o
C, 84%; iii. Jones reagent, acetone, 0 
o
C - rt; 
Scheme 2.35: Suzuki’s synthesis of kainic acid 2.1. 
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Lithiation of 2.175 using s-BuLi/2.178 followed by reaction with methylchloroformate, 
provided the desired C-2 carboxylation compound as the major product 2.176 in 
excellent stereoselectivity (49%, >98% dr). 2.177 was formed by the treatment of 2.176 
with Jones reagent
81
 via a sequential deprotection of the TBS group and oxidation of the 
resulting primary alcohol on the C3 side chain (scheme 2.35). 2.177 on subsequent 3 
steps gave the desired kainic acid 2.1. 
 
 
2.1.4.25. Tilve’s Synthesis
82 
 
A tandem Wittig-intramolecular ene reaction approach was proposed by Santosh G. 
Tilve in the year 2009. N,N-disubstituted bromoacetamide 2.179 was prepared by the N-
alkylation of benzylamine with prenyl bromide in the presence of K2CO3 followed by 
the treatment of monoalkylated benzylamine with bromoacetyl bromide. Reaction of 
bromoacetamide 2.179 with PPh3 gave the corresponding Wittig salt, which on 
deprotonation using NaOH provided the required phosphorane 2.180 in good yield 
(scheme 2.36). 
 
 
Reagents and conditions: i. (a) PPh3, C6H6. (b) 2N NaOH, 86%; ii. 50% aq. CHOCOOH, toluene, 110 
o
C, 
24 h, 2.181: 2.182 = 20:1, 60%; 
Scheme 2.36: Tilve’s synthesis of kainic acid 2.1. 
 
Phosphorane 2.180 was heated at reflux with glyoxalic acid in toluene, two reactions, 
the Wittig reaction and the intramolecular ene reaction, took place in a tandem fashion, 
yielding the desired product 2.181 and its trans analogue 2.182 as a minor product. The 
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compound 2.181 undergoes further modifications in 4 steps to give kainic acid 2.1 in 
73% yield starting from 2.181. 
 
 
2.1.4.26. Helmchen’s Synthesis
83 
 
An enantioselective total synthesis of kainic acid 2.1 was described by Günter 
Helmchen in the year 2010, which included key steps as an Ir-catalysed allylic 
amination, a diastereoselective intramolecular Pauson-Khand and Baeyer-Villiger 
reactions. The 1,6-enyne 2.183 was prepared by an Ir-catalysed allylic amination with a 
propargylic amine. The key cyclopentenone intermediate 2.184 was prepared from the 
1,6-enyne 2.183 using a protocol of intramolecular Pauson-Khand reaction with 65% 
yield (scheme 2.37). The cyclopentenone 2.184 undergoes catalytic hydrogenation, 
followed by subsequent Baeyer-Villiger rearrangement with m-CPBA to give the 
lactone 2.185. Reduction of lactone 2.185 (scheme 2.37) furnished the monoalcohol 
2.186 which has the required stereocenters for the total synthesis of kainic acid 2.1. 
 
 
Reagents and conditions: i. (a) Co2(CO)8 (1.1 eq) DCM, rt, 4 h. (b) Me3NO·2H2O (6.8 eq) 4Å MS, rt, 4 h, 
65%; ii. (a) H2 (5 bar) Pd(OH)2/C (10 wt%) EtOAc, rt, 20 h (97%). (b) m-CPBA (2.5 eq) Na2HPO4 (25 
eq) DCM, rt, 9 h (86%); iii. (a) CaCl2 (3 eq), NaBH4 (6 eq) EtOH, 50 
o
C, 4 h. (b) TBDMSCl (1.1 eq) 
imidazole (2 eq) DCM, rt, 5.5 h, 92%; 
Scheme 2.37: Helmchen’s synthesis of kainic acid 2.1. 
48 
 
2.1.4.27. Chida’s Synthesis
84 
 
In the year 2010, Noritaka Chida and co-workers successfully applied a sequential 
Claisen/Overman rearrangement to the total synthesis of kainic acid 2.1(scheme 2.38). 
E-Allylic anti-diol 2.188 was prepared in a series of steps by the use of chirality transfer 
of the three secondary hydroxyl groups embedded in ᴅ-arabinose 2.187. The crucial 
sequential Claisen rearrangement of 2.188 and the subsequent Overman rearrangement 
of 2.189 proceeded with complete diastereoselectivity, giving the trichloroacetamide 
2.190. This key acyclic intermediate 2.190 underwent a chemoselective oxidative 
cleavage in further 4 steps to provide methyl ester 2.191 in 38% yield (3 steps). 
 
 
Reagents and conditions: i. MeC(OMe)2NMe2, toluene, MS4Å, 140 
o
C in a sealed tube, 70%; ii. (a) 
CCl3CN, DBU, DCM, rt. (b) K2CO3, toluene, 120 
o
C in a sealed tube, 72% (2 steps);  iii. (a) CAN, 
MeCN/H2O, rt, 91%. (b) DEAD, PBu3, THF, 0 
o
C, 88%. (c) KOH, 
t
BuOH/H2O, 120 
o
C, 75%; 
Scheme 2.38: Chida’s synthesis of kainic acid 2.1. 
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The methyl ester 2.191 undergoes cleavage of the MPM (or PMB) group with CAN, 
followed by a Mitsunobu reaction and overall deprotection to accomplish the total 
synthesis of (-)- kainic acid 2.1. 
 
 
2.1.4.28. Aggarwal’s Synthesis
85 
 
A formal synthesis of kainic acid 2.1 by the palladium-mediated annulation of vinyl 
aziridines with Michael acceptors was reported by Varinder K. Aggarwal in the year 
2011. Vinyl aziridine 2.194 was prepared by the diastereoselective aziridination of 
imine 2.192 using chiral sulphur ylide
86
 2.193.  Palladium-catalysed annulation of 2.194 
with methyl vinyl ketone 2.195 furnished pyrrolidine 2.196 in good yield and high 
diastereoselectivity. Convertion of styryl group of pyrrolidine 2.196 into a carboxylic 
ester 2.198 was achieved through the halohydrin 2.197 which further undergoes radical 
debromination, oxidation and esterification (scheme 2.39). The ester 2.198 in further 3 
steps gives kainic acid 2.1. 
 
 
Reagents and conditions: i. NaHCO3, CH3CN, rt, 85%, 99% ee; ii. [Pd2(dba)3·CHCl3], nBu4NCl, P(o-
tolyl)3, pentane, 62%; iii. NBS, H2O, acetone, rt, 95%; 
Scheme 2.39: Aggarwal’s synthesis of kainic acid 2.1. 
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2.1.4.29. Yoshimitsu Synthesis
87 
 
Recently in the year 2011, Takehiko Yoshimitsu performed a novel photochemical C-H 
carbamoylation of an cis-fused azabicyclo[4.3.0]nonane 2.199 with PhNCO to provide a 
highly functionalized anilide 2.200 which could be used to synthesise kainic acid 2.1. 
The cis-fused azabicyclo[4.3.0]nonane 2.199 was prepared in four steps from the 
commercially available tetrahydromaleic anhydride.
88
 Photolysis of 2.199, at short-
wavelength light (<300 nm), in the presence of a photosensitizer 4,4ʹ-
dimethoxybenzophenone gave anilide 2.200 along with the disubstituted compound 
2.201. 
 
Reagents and conditions: i. PhNCO, 4,4ʹ-dimethoxybenzophenone, hν, MeCN, rt, 8.5 h; ii. (a) CAN, aq 
MeCN, 0 
o
C. (b) CDI, DMAP, THF, 60 
o
C, 65% in 2 steps; iii. 3 N NaOH, reflux then ion-exchange 
resin; 
Scheme 2.40: Yoshimitsu’s synthesis of kainic acid 2.1. 
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Yashimitsu reported this, as the first example of an intermolecular addition of a 
photochemically generated α-amino alkyl radical to phenyl isocyanate to furnish amino 
acid anilides (scheme 2.40). Anilide 2.200 was treated with CAN in aqueous MeCN at 
ambient temperature followed by protection of the resultant amine to furnish tetracyclic 
2.202 in 65% yield in 2 steps. Further hydrolysis of 2.202, followed by dehydration, 
Dess-Martin oxidation, methylation and 1,4-silylation to give silylated ketone  2.203 in 
8 subsequent steps. The compound 2.203 undergoes Baeyer-Villiger oxidation, followed 
by desilylation in two steps to give the precursor olefin 2.204. Hydrolysis of 2.204, gave 
kainic acid 2.1 as the sole product. 
 
 
2.1.4.30. Li’s Synthesis
89 
 
Li in the year 2012, reported an enantioselective synthesis of kainic acid 2.1 via SmI2-
catalysed intramolecular [3+2] cycloaddition reaction. As in previous synthesis, the 
cyclisation substrate 2.205 was derived from the commercially available ᴅ-serine 
methyl ester hydrochloride.  
 
 
Reagents and conditions: i. SmI2 (2.5 eq.), THF, rt, 81%; ii. DBU, THF, reflux, 95%; 
Scheme 2.40: Li’s synthesis of kainic acid 2.1. 
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Substrate 2.205 undergoes cycloaddition with SmI2 in THF to afford bicyclic products 
2.206 and 2.207 in 81% yield (scheme 2.40) with excellent diastereoselectivity (2.206: 
2.207 = 12:1). Treatment of 2.206 and 2.207 with DBU isomerised the double bond to 
give the bicyclic enone 2.208 in 95% yield. The enone 2.208 undergoes further 
modification to give kainic acid 2.1 in 7 subsequent steps. 
 
 
2.1.4.31. Evans’s synthesis
90 
 
Recently in the year 2012, Evans proposed a diastereoselective rhodium-catalysed ene-
cycloisomerisation reaction of alkenylidenecyclopropane to the total synthesis of kainic 
acid 2.1.  
 
Reagents and conditions: i. (a) DMP, pyridine, Ph3PCHCO2Et, DCM/MeCN, 40 
o
C, 77%. (b)                 
1-Vinylcyclopropyl tosylate, cat. Pd(PPh3)4, THF, then pronucleophile, NaH, THF, rt, 84%; ii. DIBAL-H, 
BF3·OEt2, DCM, -78 
o
C – rt, 70%; iii. [Rh(COD)Cl]2 (4 mol%), tri-p-tolyl phosphate (24 mol %), THF, 
135 
o
C (sealed tube), 69%; 
Scheme 2.41: Evan’s synthesis of kainic acid 2.1. 
 
Commercially available amino alcohol 2.209 was subjected to one-pot sequential Dess-
Martin oxidation, followed by a concomitant Wittig homologation to give the 
conjugated ester in 77% yield, which further underwent palladium-catalysed allylic 
amination to afford α,β-unsaturated ester 2.210 in 84% yield.91 DIBAL-H reduction of 
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ester 2.210 afforded allylic alcohol 2.211 in 70% yield. The key rhodium-catalysed ene-
cycloisomerisation reaction of 2.211 with rhodium complex furnished anti,syn-2,3,4-
trisubstituted pyrrolidine skeleton 2.212 in 69% yield(scheme 2.41) with excellent 
diastereocontrol(ds ≥ 19:1). The compound 2.212 undergoes further modification in 4 
subsequent steps to give kainic acid 2.1. The total synthesis of kainic acid 2.1 was 
accomplished by Evan in 8 steps from 2.209 in 17% overall yield. 
 
 
2.1.4.32. Poisson’s Synthesis
92 
 
Poisson in the year 2012, reported a Diels-Alder-based total synthesis of kainic acid 2.1. 
Enone 2.213 and 2.214 were prepared in 9 steps from commercially available 
hydroxyproline in 70% overall yield.  
 
 
Reagents and conditions: i. 2.215, toluene, Δ or THF, rt; ii. HCl (1M); iii. (a) 2.218, LiOH, NEt3, toluene 
30% (from 2.213). (b) 2.219, KOH/THF, 31% (from 2.214); 
Scheme 2.42: Poisson’s synthesis of kainic acid 2.1. 
 
The α,β-unsaturated ester 2.213 and aldehyde 2.214 showed similar behaviour towards 
electron-rich dienes. In refluxing toluene, ester 2.213 and aldehyde 2.214 reacted with 
Rawal’s diene87 to give corresponding cycloadducts 2.216 and 2.217 (scheme 2.42). 
Hydrolysis of cycloadducts 2.216 and 2.217 provided only enones 2.218 and 2.219 
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respectively. β-keto ester 2.218 on saponification, followed by decarboxylation of the 
resultant acid, provided enone 2.220 in 4 steps with 30% overall yield. β-keto aldehyde 
on decarbonylation with KOH gave the same enone 2.220 in 3 steps with 31% overall 
yield. The enone 2.220 undergoes further modification in 7 subsequent steps to give the 
precursor olefin 2.221, which has the required stereocenters for the total synthesis of 
kainic acid 2.1. 
 
 
Reagents and conditions: i. 2.223, DCM, 15 kbar; ii. KHSO4 aq, THF; iii. DBU, toluene, 81%; iv. (a) O3, 
-116 
o
C, DMS.  (b) CH2N2, 70% (3 steps); 
Scheme 2.43: Poisson’s synthesis of kainic acid 2.1. 
 
Similar to the (scheme 2.42) Poisson attempted high pressure [4 + 2] cycloaddition of 
ester 2.222 with Danishefsky’s diene87 2.223. The cycloadditon of ester 2.222 with 
diene 2.223 in DCM, at room temperature under 15 kbar after 82h gave the cycloadduct 
2.224 in 96% yield (scheme 2.43). The cycloadduct 2.224 was converted into a mixture 
of 2.225 and the enone 2.226 by treatment with KHSO4. The compound 2.225 was 
converted to 2.226 by treatment with DBU in hot toluene. The enone 2.226 was 
converted to unstable trimethylsilyl ester 2.227 in 5 steps.
87
 The unstable compound 
2.227 was ozonolysed at low temperature followed by reaction with diazomethane to 
give aldehyde diester 2.228 in 3 steps with 70% overall yield. The diester 2.228 has the 
required stereocenters for the total synthesis of kainic acid 2.1. 
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2.1.4.33. Parsons Synthesis
93 
 
In an effort to produce new synthetic routes to the kainoids family, kainic acid was 
synthesised by Parsons and co-workers by using amino acid chemistry. It started with  
ᴅ-serine methyl ester, which was treated with triphosgene to afford the ester 2.229 
quantitatively. N-alkylation of the ester 2.229 with 1-bromo-3-methyl-2-butene in the 
presence of sodium hydride gave the N-alkylated ester 2.230 in 78% yield. The 
compound 2.230 was reduced, to give aldehyde, which under Wittig reaction conditions 
gave the unsaturated ester 2.231.  
 
 
Reagents and conditions: i. NaH, THF + DMF (4:1), 1-bromo-3-methyl-2-butene, 0 
o
C – rt, 78%; ii. 
DIBAL-H, CH2Cl2, -78 
o
C, followed by NH4Cl (C6H5)3P=CHCO2CH3, -20 oC, (83%); iii. MW, 
diethylaniline, 200 
o
C, 4 h (80% 7:1 in favour of 2.232); 
Scheme 2.41: Parsons’s synthesis of kainic acid 2.1. 
 
The solution of the unsaturated ester 2.231 was heated in diethylaniline at 200 
o
C in a 
microwave to give the ene-product 2.232 and an allo-kainate precursor 2.233 in 80% 
yield with a diastereomeric ratio of 7:1 favoring 2.232. The ene-product 2.232 has the 
required stereocenters for the total synthesis of kainic acid 2.1(scheme 2.41). The total 
synthesis of kainic acid 2.1 was completed with 20% overall yield.
  
 
 
 
 
 
 
 
 
 
 
3. Results and Discussion 
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3.1. Introduction  
Following on from the previous work of Greenwood
94
, Adrian Murray
95
 and Jason Lai
96
 
it was the aim of the project to: 
 
 
1) Further improve upon the previously developed procedure for the 
preparation of multi-gram quantities of oxazolidinone 2.240.  
2) Further investigate the diastereofacial selectivity of the oxazolidinone 
precursor 2.240. 
3) Using the oxazolidinone precursor 2.240, to find a novel route to the total 
synthesis of (-)-kainic acid 2.1. 
4) Using the same precursor 2.240 for an attempted total synthesis of allokainic 
acid 2.2 and members of the other kainoid family. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
3.1.1. Chemistry of the precursor oxazolidinone 2.240. 
 
3.1.1.1. Formation of oxazolidinone 2.240: 
 
A modified procedure developed by Jason Lai
96
 was used for the formation of the key 
oxazolidinone 2.240 (scheme 3.1). 
 
 
Reagents and conditions: i) SOCl2, MeOH; ii) Boc2O, 
i
Pr2(Et)N, DCM (86%); iii) I2, PPh3, Imidazole, 
DCM, 0 
o
C – rt (88%); iv) DBU, toluene, 80 oC, (75%); v) NaBH4, THF/CH3CN (85%); vi) DAST, DCM 
(86%). 
 
Scheme 3.1: Synthesis of oxazolidinone 2.240. 
 
Commercially available trans-4-hydroxy–L-proline 2.234 was subjected to Fisher 
esterification
97
 to yield the corresponding hydrochloride salt 2.235. This was followed 
by Boc protection of the pyrrolidine nitrogen 2.235 using Boc anhydride and Hünig’s 
base which gave the desired Boc protected ester 2.236 in 86% yield. The hydroxyl 
group of ester 2.236 was converted to a better leaving group.  
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Reagents and conditions: i. (PhSe)2, NaBH4, EtOH, Δ; ii. H2O2, pyr, DCM, -78 
o
C – rt. (65% over 2 
steps); 
Scheme 3.2: Synthesis of 2.243. 
 
Previous methods
94-96
 had involved conversion of the hydroxyl group to a mesylate to 
form mesyloxyprolinate 2.241. PhSe
- 
anion was the used to displace the mesylate to 
give the intermediate selenide 2.242. The selenide 2.242 was converted to the 
corresponding alkene 2.243 by oxidation with hydrogen peroxide followed by 
elimination of the resulting selenoxide, to give alkene 2.243 in 65% yield (scheme 3.2).  
 
In order to avoid the inherent toxicity of organo-selenium compounds and to increase 
the yield, we developed another procedure within our group. This procedure involved 
replacing the hydroxyl group with iodine (as shown in scheme 3.1). The X-ray crystal 
structure of one of the two isomers of iodo-pyrrolidine dicarboxylate 2.237 obtained is 
shown below (figure 3.1). This was followed by the elimination of the iodine, using the 
bulky base DBU.  
 
 
Figure 3.1: Crystal structure of 2.237. 
 
During the elimination, we obtained two separable diastereomers 2.238 and 2.244 in 
(9:1) ratio with the required diastereomer as the major product (scheme 3.3). 
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Reagents and conditions: i. DBU, toluene, 80 
o
C, (89%) (2.238: 2.244 = 9:1); 
Scheme 3.3: Formation of diasteromers 2.238 and 2.244. 
 
The alkene 2.238 was converted to the corresponding alcohol 2.239 using NaBH4 in 
THF/CH3CN. Although different reagents such as, DIBAL, LiAlH4 could be used for 
the conversion of ester to alcohol,
95
 NaBH4 gave higher yields (scheme 3.1). 
 
Oxazolidinone 2.240 was first formed by Pyne,
98
 whose synthesis involved using a ring 
closing metathesis to construct the bicyclic ring system. The styrene derivative 2.246 
underwent a RCM reaction, using Grubbs’ 2nd generation catalyst to give 2.240 in an     
82% yield (scheme 3.4). 
 
 
Reagents and conditions: i. Grubbs II, (73-82 %); 
Scheme 3.4: Synthesis of oxazolidinone 2.240. 
 
The alcohol 2.239 was converted to bicyclic oxazolidinone precursor 2.240 by treatment 
with DAST in DCM in 86% yield using the procedure followed by Greenwood
94 
(scheme 3.1). 
Recently in the year 2011, Pinhas
99
 and co-workers were able to perform a solvent and 
catalyst free conversion of an aziridine to an oxazolidinone using only carbon dioxide at 
low pressure and at room temperature (table 3.1).  
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Table 3.1 High Speed Ball Milling Reactions: 
 
 
 
When aziridine 2.249 was stirred, with no solvent or catalyst, under CO2 with 3 atm 
pressure for 12 h, the yield of oxazolidinone 2.250 was 37%. The high speed ball 
milling (HSBM) method generated oxazolidinone in nearly quantitative yield with only 
one regioisomer. In order to decrease the time of the reactions, (HSBM) was 
investigated. Mechanical energy generated from HSBM has been shown to give high 
yields and an increase in the rate of chemical reactions, especially those reactions done 
without any solvent. The HSBM apparatus uses a small steel ball in a steel vial with 
high speed shaking to achieve small particle sizes through milling. Subsequent 
collisions of the milling ball with the sides of the reaction vessel provide mechanical 
energy to overcome the activation barrier generated in the reaction.
100,101 
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3.1.1.2 Diastereofacial selectivity of the oxazolidinone precursor 2.240. 
 
Greenwood was the first to discover that reactions on the double bond of oxazolidinone 
2.240 occurred in a diastereoselective fashion.
102,103
 For instance it was found that 
irradiation of oxazolidinone 2.240 with dioxane 2.257 resulted in a cyclobutane 
photoadduct 2.258 with complete regio- and stereoselectivity together in 38% plus 
unreacted starting materials(scheme 3.6). The photocycloaddition occurred only on the 
more sterically congested concave face of oxazolidinone 2.240. 
 
 
 Reagents and conditions: i. hv, EtOAc (38%); 
Scheme 3.6: Formation of cyclobutane photoadduct 2.258. 
 
Similar control of the stereochemistry was also observed by Greenwood using pyranone 
2.259, which on irradiation with oxazolidinone 2.240 gave the photoadduct 2.260 
(scheme 3.7).
102,103 
 
 
Reagents and conditions:  i. hv, EtOAc (43%); 
Scheme 3.7 
 
Following on from these photochemical reactions, Greenwood and Adrian Murray 
discovered the same stereoselectivity occurred when oxazolidinone 2.240 was treated 
with a series of electrophiles (scheme 3.8).
103
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Reagents and conditions i) m-CPBA (33%) OR DMDO (80%); ii) OsO4 (83%); iii) NIS (60%); iv) PhSCl 
(65%); 
Scheme 3.8 
 
As shown in the (scheme 3.8), electrophilic addition to oxazolidinone 2.240 was 
exclusively directed onto the endo face as expected.
103
 Additional examples of 
regiocontrol were then shown by Greenwood in the formation of compounds 2.264 and 
2.266.
102,103
 The nucleophilic attack of hydroxide and chloride on activated iodonium 
2.263 and sulphonium 2.265 intermediates was shown to occur at the least hindered 
carbon. 
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Further investigations by Jason Lai,
96
 involved an intermolecular 1,3-dipolar 
cycloaddition. Treating oxazolidinone 2.240 with a series of nitrile oxides (2.269-
2.276), which act as the electrophiles, gave a range of tricyclic isoxazoles (2.277-2.284). 
Nitrile oxides were generated in situ in these cycloadditions in the presence of Et3N 
(scheme 3.9). 
 
 
 
Reagents and conditions: i. 2.240, Et3N, C6H6, rt; ii. 2.240, PhNCO or TsCl, Et3N, C6H6, rt; 
Scheme 3.9 
 
An explaination for the diastereoselectivity (scheme 3.9) was believed to be due to the 
distribution of electron density within the alkene 2.240. An investigation was carried out 
within the Parsons group by Eddy Viseux, which gave a quantitative theoretical 
explanation of the origin of disastereofacial selectivity for both the electrophilic 
dihydroxylation and epoxidation of alkene 2.240.
103
 Using ab initio calculations at the 
6-31G
*
 level, the molecular orbitals of the most stable conformation of oxazolidinone 
2.240 were calculated (using the MM
+ 
set). 
 
 
As shown in figure 3.2 the model calculated by Eddy Viseux suggested that: 
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1. There was a distortion in the HOMO that led to greater electron density being placed 
on the endo face of the compound. This may explain the observed diastereofacial 
selectivity of the electrophilic attack. 
2. The nitrogen lone pair appears not to be in conjugation with the carbonyl system. 
Further evidence for this was provided by the IR stretch frequency for the C=O at 1751 
cm
-1
. This is higher than the range usually expected for such a carbamate system. 
 
 
 
Figure 3.2: 6-31-G
*
 representation of the HOMO of oxazolidinone 2.240.
103 
 
Pyne
98
 also observed the same diastereofacial selectivity when dihydroxylating 
oxazolidinone 2.240 with osmium tetroxide. However they concluded that the 
stereochemical outcome was due to the pseudo-axial protons H-10 and H-12, which 
cause the exo face of oxazolidinone 2.240 to be more sterically hindered for the 
electrophilic attack (figure 3.3). 
 
 
 
 
           
 
 
 
 
 
Figure 3.3: Stereochemical model (Spartan AM1) of oxazolidinone 2.240.
98
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3.2. Studies towards the synthesis of kainic acid 2.1. 
 
3.2.1. Retrosynthesis of kainic acid 2.1: 
 
For the total synthesis of kainic acid 2.1, we devised a route starting from a cheap and 
readily available starting material trans-4-hydroxy-L-proline 2.234 (scheme 3.10). This 
would be then transformed into the key oxazolidinone 2.240, where the stereochemistry 
at C-2 is fixed into one correct position for kainic acid 2.1. Oxazolidinone 2.240 would 
be then subjected to 1,3-dipolar cycloaddition with ethyl nitrile oxide in the presence of 
TsCl and Et3N to give the tricyclic isoxazole 2.279. Reduction of 2.279 by treatment 
with Raney Ni under H2 atmosphere with MeOH as solvent would give β-hydroxy 
ketone 2.288. The resulting ketone 2.288 on dehydration using p-TSA would give enone 
2.287. The enone 2.287 would be then transformed into the key dicarboxylate 2.286 by 
1,4 addition, where the stereochemistry of C-3 and C-4 is fixed into the correct position 
for kainic acid 2.1. The dicarboxylate 2.286 would further undergo Wittig reaction 
followed by decarboxylation to give bicyclic acid 2.285. The compound 2.285 would be 
then transformed into kainic acid 2.1 according to the procedure devised by Parsons.
93 
 
 
 
Scheme 3.10: Retrosynthesis of kainic acid 2.1. 
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3.2.2. 1,3-Dipolar cycloaddition of oxazolidinone 2.240.  
 
Oxazolidinone 2.240 was prepared by the modified procedure of Jason Lai
96 
(scheme 
3.11).  The oxazolidinone 2.240 was subjected to 1,3-dipolar cycloaddition using a 
nitrile oxide electrophile generated in situ. Triethylamine was added to a solution of 
oxazolidinone 2.240 and nitroethane in the presence of TsCl which gave only one 
diastereoselective product, a tricyclic isoxazole 2.279 in 68% yield. The structure of the 
resulted adduct was confirmed with X-ray crystallographic analysis by Jason Lai
96
 
(figure 3.4).  
 
 
Reagents and conditions: i. EtNO2, TsCl, Et3N, benzene, 12 h, 68%; 
Scheme 3.11: Synthesis of tricyclic isoxazole 2.279. 
 
Figure 3.4: X-ray crystallographic structure of 2.279. 
 
Previous attempts by Jason Lai
96
 to form tricyclic isoxazole 2.279 involve generation of 
ethyl nitrile oxide 2.271 in situ by a procedure developed by Mukaiyama and 
Hoshino.
104
 In that procedure, nitroethane was dehydrated with phenyl isocyanate in the 
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presence of triethylamine, to generate the desired ethyl nitrile oxide 2.271. However, in 
this 1,3-dipolar cycloaddition, diphenyl urea 2.289 was precipitated as a by-product in 
the solution, which is difficult to separate from the desired tricyclic isoxazole 2.279 
even by flash chromatography due to similar solubilities
96
 (scheme 3.12)
 
. 
 
 
Reagents and conditions: i. PhNCO, Et3N, Δ, C6H6; 
Scheme 3.12 
 
In order to improve the yield and replace the potentially carcinogenic benzene as 
solvent, we repeated the same reaction using a variety of common alternatives (table 
3.2). In each case the reaction never went to completion, and the yield was lower 
compared to the use of benzene as solvent. Hünig’s base was used in place of 
triethylamine but this only resulted in a lowering of the yield of isoxazole 2.279. 
Although we tried to increase the time of the reaction from 12 hrs to 7 days under the 
same conditions, we could not manage to get the completion of reaction, and the yield 
was low. We continued with benzene as solvent which gave the maximum yield.  
 
Table 3.2: Formation of tricyclic isoxazole 2.279. 
 
S.No  Reagents and Conditions (i) Solvent Yield (%)
* 
1  2.240, EtNO2, Et3N, TsCl, 0 
o
C - rt,        
7 days. 
C6H6 68 
2  Same as above Toluene 55 
3  Same as above THF 50 
4  Same as above DCM       58 + 15 (2.290)  
5  Same as above CH3CN 62 
6  Same as above Et2O 45 
7  2.240, EtNO2, Hünig's base, TsCl,        
0 
o
C - rt, 12 h. 
C6H6 60 
 
* 
= In each case starting material was also recovered. 
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When DCM was used as a replacement solvent to prepare tricyclic isoxazole 2.279, we 
observed something unconventional compared to scheme 3.11. We obtained an unusual 
byproduct 2.290 (scheme 3.13). The byproduct 2.290 was stable and could be isolated 
by flash column chromatography to give a crystalline solid. When analysed by X-ray 
crystallography, we discovered this to be the oxysulfonyl chloride compound 2.290 as 
shown below (figure 3.5) which in turn reduces the yield of the reaction. The byproduct 
2.290 could be avoided by using benzene as solvent. Interestingly this byproduct 2.290 
was not seen in any other reaction using alternative solvents (table 3.2). 
 
 
 
Reagents and conditions: i. EtNO2, TsCl, Et3N, DCM, 12 h. 
Scheme 3.13 
 
 
Figure 3.5: X-ray crystallographic structure of 2.290. 
 
An explanation for this result could be, TsCl acting as a chlorinating agent in presence 
of DCM and oxazolidinone 2.240.  
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Reagents and conditions: i. LDA, TsCl, THF, 83%; 
Scheme 3.14 
 
Brummond
105
 described α-chlorination of ketones using TsCl, in which α-chloroketones 
are formed in good yield. Thus, inferring TsCl is chlorinating agent. The ketone 2.291 
on treatment with TsCl in presence of LDA gave chlorinated ketone 2.292 in 83% yield 
(scheme 3.14). 
 
The plausible mechanism for the formation of byproduct 2.290 is show below (scheme 
3.15).  
 
 
Scheme 3.15 
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Triethylamine reacts with nitroethane 2.271 to give the nitronic acid 2.293, which reacts 
with TsCl 2.294 to give the nitroxy-sulfonyl compound 2.295. Chloride ion reacts with 
2.295 to give oxy-sulfonyl chloride 2.296. Oxazolidinone 2.240 reacts with 2.296 to 
give positively charged oxazolidinone chloride 2.297 and aromatic anion 2.298. The 
anion attacks the compound 2.299 from the least hindered side, to give the more stable 
novel aromatic oxy-sulfonyl chloride 2.290. Consequently, we proved that the 
oxazolidinone 2.240 ring plays a pivotal role in the formation of tricyclic isoxazole 2.27 
(scheme 3.11-3.15). 
 
 
3.2.3. Attempted formation of bicyclic isoxazole  
 
Subsequently upon the preparation of tricyclic isoxazole 2.279, we envisaged another 
route which could have potentially avoided de-protection in later steps (scheme 3.16).  
 
 
 
 
 
Reagents and conditions: i. EtNO2, TsCl, Et3N, DCM, 12 h; 
Scheme 3.16 
 
A failed attempt to use the similar conditions (scheme 3.11) on the double bond of the 
Boc-protected ester 2.238 to get bicyclic isoxazole 2.300, which could have reduced 
further steps in opening of the oxazolidinone ring 2.240. Unfortunately we only 
recovered the starting material 2.238 (scheme 3.16).  
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In order to mimic the reaction conditions used in scheme 3.11 on the double bond of 
trifluoro compound 2.302, we tried to obtain 2.303. We failed to get the desired product 
2.303 and instead we recovered the starting material (scheme 3.17).  
 
 
Reagents and conditions: i. EtNO2, p-TsCl, Et3N, DCM, 12 h; 
Scheme 3.17 
 
 
3.2.4. Reduction of isoxazole ring:  
 
The isoxazole ring is a biologically important entity which is a component of some of 
the nucleoside analogs.
106
 The isoxazole structure is found in some pharmacologically 
interesting natural products, for example, cycloserine
107
 2.304 and acivicin
108
 2.305 
(figure 3.6). Cycloserine 2.304 is an antibiotic used in the treatment of tuberculosis,
109
 
effective against Mycobacterium tuberculosis.
110
 Acivicin 2.305 is used as an 
antineoplastic agent, which acts as a glutamine analog antimetabolite.    
 
 
                                     
                             Cycloserine                                            Acivicin 
Figure 3.6: Structure of cycloserine 2.304 and acivicin 2.305 
 
There are a variety of methods for the transformations of isoxazolines into other useful 
functionality
111-114
. For instance, dehydrogenation of intermediate iminoalcohol arising 
from N-O bond cleavage of 2.306 affords β-hydroxy nitriles 2.307. The N-O bond 
cleavage of 2.308 followed by hydrolytic workup provides β-hydroxyketone 2.309. 
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Complete reduction of the isoxazoline ring 2.310 provides γ-aminoalcohols 2.311          
(scheme 3.18).  
 
 
 
Reagents and conditions: i. Na2CO3, MeOH, rt, 12 h, 66%; ii. (a) H2, Raney Ni, HOAc. (b) NaHCO3, 
H2O; iii. (a) DIBAL. (b) Resolution; 
 
Scheme 3.18 
 
According to literature
115
 the most popular methods for reduction of isoxazoline 2.312 
is hydrogenation with Raney Ni
116 
or Pd/C
117
 in the presence of boric acid in 
methanol/water at room temperature leads to β-hydroxy ketones 2.314 (scheme 3.19). 
The stereochemistry of the reactant 2.312 is retained in the product 2.314. 
 
 
 
Scheme 3.19 
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Reaction of 4,5-Dihydroisoxazoles 2.315 with sodium metal in ethanol or by NaBH4 
and  NiCl2·(H2O)6 in methanol at -30 
o
C yield β-amino alcohols 2.316 (scheme 3.20).118 
 
 
 
Scheme 3.20 
 
 
3.2.5. Dehydration of the β-hydroxy ketone using p-TSA. 
 
Dehydration of a β-hydroxy ketone can be done by both base catalysed or acid catalysed 
method. The mechanism can be seen below (scheme 3.21). 
 
 
 
Scheme 3.21 
 
 
 
 
 
 
74 
 
3.2.6. Formation of enone 2.287 
 
Returning to tricyclic isoxazole 2.279 the reduction was conducted using Raney Ni in 
the presence of boric acid in methanol/water at room temperature. We hoped to obtain 
the β-hydroxy ketone 2.288 (scheme 3.22). However, β-hydroxy ketone 2.288 was 
difficult to isolate and underwent dehydration using a catalytic amount of p-TSA·H2O in 
toluene using Dean-Stark apparatus
119 
to give enone 2.287 in 89% yield (starting from 
2.279) (scheme 3.22). The resulting enone 2.287 was confirmed by X-ray 
crystallographic analysis (figure 3.7). β-Hydroxy ketone 2.288 was isolated by Jason 
Lai
96
, although the yield of enone was very low, but we found it difficult to isolate and 
yield of enone was improved to a large extent. 
 
 
Reagents and conditions: i. Raney Ni, H2, Boric Acid, Methanol/Water (5:1), rt; ii. p-TSA·H2O, Toluene, 
reflux (80
o
C), 89% overall yield;  
Scheme 3.22: Synthesis of enone 2.287. 
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Figure A of 2.287. 
           
 
Figure B of 2.287. 
 
Figure 3.7 : X-ray crystallographic structure of 2.287. 
 
 
3.2.7. Michael addition reaction. 
 
Michael reaction
120,121
 is an important carbon-carbon bond-forming reaction. In classical 
example of Michael reaction, the reaction is between Michael donor (usually diethyl 
malonate) and Michael acceptor. The enone 2.287 acts as a good Michael acceptor. The 
nucleophilic conjugate addition occurs usually with α,β-unsaturated carbonyl 
compounds, and such nucleophilic addition are called as nucleophilic conjugate addition 
or 1,4-nucleophilic addition. An example of highly efficient C-C bond-forming 
reactions in aqueous media catalysed by monomeric vanadate species is reported by 
Kaneda
122
 (scheme 3.23). Here the substrate 2.323 reacts with enones 2.324 and 2.326 
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in presence of catalyst VAp and VAp-hw to give esters 2.325 and 2.327 respectively in 
high yields.
122
 
 
Reagents and conditions: i. VAp (0.008 g), H2O (50 mL), 40 
o
C, 1.5 h, 92%; ii. VAp-hw, H2O (3 mL),    
50 
o
C, 0.5 h, 99%; 
 
Scheme 3.23 
 
The enone in compound 2.287 should undergo 1,4-nucleophilic addition in a similar 
fashion to the (scheme 3.23) as above. The proposed Michael reaction for enone 287, 
can be seen below (scheme 3.24).  
 
 
Reagents and conditions i: NaH, THF, dimethyl malonate, 0 
o
C – rt, 90%, (2.328:2.329 = 1:1); 
Scheme 3.24: Michael reaction of enone 2.287. 
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We expected to get the diester 2.286, which could have formed the key intermediate for 
the total synthesis of kainic acid 2.1 (scheme 3.24). This diester 2.286 has the same 
stereochemistry as in kainic acid 2.1. On Michael reaction of enone 2.287 with the 
carbanion derived from dimethyl malonate, we isolated two diastereomers 2.328 and 
2.329 in 1:1 ratio (scheme 3.24). The overall yield of the reaction was 90%. Both the 
diastereomers 2.328 and 2.329 were solids, but we could only obtain X-ray quality 
crystals of 2.329, by means of which we could determine the exact structure of the 
compound 2.329 (figure 3.8). In (scheme 3.24) it is clear that the nucleophile can attack 
from either side of the enone 2.287 and due to the bulk, the anti stereochemistry is 
formed.  
 
 
 
 
Figure 3.8: X-ray crystallographic structure of 2.329. 
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We attempted to utilise compounds 2.328 and 2.329 to further investigate the total 
synthesis of the kainates. The diester 2.328 has the required stereochemistry for the total 
synthesis of allokainic acid 2.2 (scheme 3.25 shown below).  
 
 
Scheme 3.25 
 
 
3.2.8. Epimerisation of C-4 group. 
 
Jack E. Baldwin
123
 in the synthesis of heteroaromatic acromelic acid analogues from 
kainic acid 2.1 used DBU to epimerise the C-4 position of 2.331 (scheme 3.26). 
 
 
 
Reagents and conditions i: DBU, Toluene, rt; ii: LiHMDS, TMSCl, -78 oC, then PhN+Me3Br3-; 
Scheme 3.26 
 
We desired to use the same method used by Baldwin, for the epimerisation of the 
diastereomers 2.328 and 2.329 in order to obtain isomers with the same cis-
stereochemistry (scheme 3.27).  
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Reagents and conditions: i. DBU, toluene, rt; 
Scheme 3.27 
 
 
3.3. Studies towards the formal synthesis of allokainic acid 
2.2. 
 
3.3.1. Decarboxylation of diastereomers 2.328 and 2.329. 
 
There are two possible routes for the conversion of diester 2.328 into acetate 2.233 
(scheme 3.28). In route (a), the diester 2.328 undergoes a Wittig reaction to convert into 
alkene 2.338 and then a further Krapcho decarboxylation
124
 to give acetate 2.233. In 
route (b) the diester 2.328 undergoes Krapcho decarboxylation first, followed by Wittig 
reaction to give acetate 2.233.  
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Scheme 3.28 
 
 
We started with route (b) (scheme 3.28), as the ester 2.334 could be used for the 
epimerization of the C-2 group (scheme 3.27). In the route (b) Krapcho decarboxylation 
is followed by Wittig reaction. 
 
 
3.3.1.1. Krapcho decarboxylations: 
 
Paul Krapcho studied the synthetic applications and mechanism of the decarboxylations 
of geminal diesters and related systems in DMSO by water and /or by water with added 
salts.
124
 Most of the protecting groups in the substrate are tolerated under the reaction 
conditions, with the stereochemistry retained. Some examples can be seen in (scheme 
3.29). The compound 2.339 undergoes Krapcho decarboxylation using NaCl in presence 
of DMSO to give exclusively 2.340 in 80% yield. The diester 2.341 undergoes 
decarboxylation using NaCN in presence of DMSO to give the bicyclic ester 2.342 in 
63% yield. We preferred NaCl over NaCN as the yields were high (scheme 3.29). 
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Reagents and conditions: i. NaCl, DMSO, 160 
o
C; ii. NaCN, DMSO, 160 
o
C; 
Scheme 3.29 
 
The decarboxylation was tried on the diesters 2.328 and 2.329 (formed in scheme 3.24). 
There was no desired product formed and the starting material was decomposed without 
any isolated products (scheme 3.30).  
 
 
Reagents and conditions:  i. NaCl, DMSO/H2O, 170 
o
C, 0% (starting material decomposed); 
Scheme 3.30 
 
We decided to attempt the alternative route (a) (scheme 3.28), and apply Wittig 
conditions on the diesters 2.328 and 2.329 to convert the ketone group to alkene group. 
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3.3.2. Wittig reactions. 
 
Wittig
125-127
 reactions are the most commonly used reactions in organic synthesis for the 
conversion of a keto group to alkene. For the Wittig reaction, we used the conditions 
used by Stephen Hanessian
48
 in the stereoselective synthesis of kainic acid 2.1 and 
allokainic acid 2.2 (scheme 3.31). 
 
 
 
Scheme 3.31: Hanessian’s Wittig reaction. 
 
We observed some noteworthy results shown below (scheme 3.32). We started with 
compound 2.328 which in subsequent steps could give allokainic acid 2.2. Here we got 
the desired alkene 2.338 in 72% yield and there was a remarkable change in 
stereochemistry of the starting material 2.328 which gave the opposite diastereomer 
2.329 in 10% yield as a by-product. 
  
 
Reagents and conditions:  i. n-BuLi (2.5M), -78 
o
C, Ph3PMeBr/THF, (2.338 =72%), (2.329 = 10%); 
Scheme 3.32 
 
Then we tried the Wittig reaction using similar conditions used above (scheme 3.32) for 
the other diastereomer 2.329. Here we got the alkene 2.343 in 81% yield and there was 
some starting material recovered (scheme 3.33). Here we could not observe any change 
in stereochemistry. 
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Reagents and conditions:  i. n-BuLi (2.5M), -78 oC, Ph3PMeBr/THF, 81%; 
Scheme 3.33 
 
At this point, we tried Wittig reaction on the mixture of both the diastereomers 2.328 
and 2.329 and here we got the alkenes 2.338 and 2.343 in 77% overall yield, with the 
later 2.343 as the major product (scheme 3.34). The alkenes 2.338 and 2.343 were 
difficult to separate when combined together. 
 
Reagents and conditions:  i. n-BuLi (2.5M), -78 oC, Ph3PMeBr/THF, overall 77%, 2.343 (major product); 
Scheme 3.34 
 
 
3.3.3. A formal synthesis of allokainic acid 2.2. 
 
The alkene 2.338 on decarboxylation would give rise to the formal synthesis of 
allokainic acid 2.2. The molecule 2.338 was subjected to Krapcho decarboxylation 
(scheme 3.30). We performed the reaction (scheme 3.35) over a range of different 
temperatures, with similar conditions and results are summarised in Table 3.2. 
 
In the Table 3.2, the reaction under different temperatures can be seen. The optimum 
temperature for this reaction is shown to be between 170 
o
C - 175 
o
C. If the temperature 
is above 175 
o
C then the reactant is completely decomposed without any desired 
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product 2.233. If the temperature is maintained below 170 
oC, then the reaction doesn’t 
go to completion and we can recover the starting material 2.338. 
 
 
 
Reagents and conditions:   i: NaCl, DMSO/H2O, 170 
o
C, 83%; 
Scheme 3.35  
 
Table 3.2. Krapcho reaction conditions 
 
 
 
Rxn 
 
Reagents and 
conditions 
 
Temperature  
(
 o
C) 
 
Time 
(h) 
 
Inference 
 
1) 
 
2.338 ,NaCl, 
DMSO/H2O 
 
 
140  
 
8 
 
2.338 
 
2) 
 
2.338 ,NaCl, 
DMSO/H2O 
 
160  
 
8 
 
Trace 2.233, + 2.338. 
 
3) 
 
2.338 ,NaCl, 
DMSO/H2O 
 
170 -175  
 
8 
 
2.233 (75 %) 
 
4) 
 
2.338 ,NaCl, 
DMSO/H2O 
 
180 -190  
 
2 
 
Decomposed. 
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With the formation of 2.233, we completed the formal synthesis of allokainic acid.
48,88
 
The opening of the oxazolidinone followed by oxidative deprotection gives allokainic 
acid 2.2 (scheme 3.36). 
 
 
Reagents and conditions:   i. NaOH, (Boc)2O, CH2N2, 88%, overall; ii. Jones oxidation, CH2N2, 86%; iii. 
KOH, TFA, DOWEX H
+
, 65%; 
Scheme 3.36 
 
We performed the same decarboxylation with the opposite diastereomer 2.343 which 
gave the ester 2.345 (scheme 3.37). 
 
 
Reagents and conditions: i. NaCl, DMSO/H2O, 170 
o
C, 75%; 
Scheme 3.37 
 
This ester 2.345 on further ring opening followed by oxidative deprotection would give 
the compound 2.346 which is the epimer of kainic acid 2.1 (scheme 3.38). 
 
 
Scheme 3.38 
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3.3.4. Attempts to change the stereochemistry at C-3 position. 
 
Previous attempts were unsuccessful to change the stereochemistry at C-4 position 
(scheme 3.27). In our repeated attempts to convert the diastereomers 2.328 and 2.329 
into cis-compounds 2.286 and 2.347 respectively, we found a suitable method 
developed by Almudena Rubio
59
 which can be used to get the desired stereochemistry 
(scheme 3.39). 
 
 
 
Scheme 3.39 
 
Almudena Rubio et al. using PhSeCl could adjust the stereochemistry at both the C-2 
and C-3 positions of compound 2.348. It started with the deprotonation of 2.348 with 
KHMDS in dry THF at 0 
o
C which was then reacted with PhSeCl. The selenated 
product 2.349 was oxidized with hydrogen peroxide
128
 in THF at 0 
o
C, to give the olefin 
2.350. Asymmetric hydrogenation of the double bond was achieved in ethanol with 
PtO2 as catalyst to give all-cis prolinate 2.351. It should be noted that this final step 
required 15 days to reach completion (scheme 3.40). 
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Reagents and conditions: i. a) KHMDS/THF/0 
o
C. b) PhSeCl/0 
o
C – rt; ii. H2O2/THF/0 
o
C; iii. 
H2/PtO2/EtOH; 
Scheme 3.40 
 
The change in stereochemistry to get the desired cis compounds 2.286 and 2.347 was 
prerequisite to complete the total synthesis of kainic acid 2.1. Based on the work 
conducted by Rubio,
59
 PhSeCl was reacted with 2.329 in the presence of KHMDS in 
THF at   0 
o
C (scheme 3.41) to give selenated product 2.352.  
 
 
Reagents and conditions: i. KHMDS/THF/0 
o
C, PhSeCl/0 
o
C – rt, 78%; 
Scheme 3.41 
 
We tried an array of reactions using three separate oxazolidinone starting materials, all 
of which could further be useful in the synthesis of kainic acid 2.1. However we failed 
to get any of the desired compounds and recovered the starting material (scheme 3.42).  
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Reagents and conditions: i. KHMDS/THF/0 
o
C, PhSeCl/0 
o
C – rt, starting material was recovered. 
Scheme 3.42 
 
The same reaction conditions based on (scheme 3.41) were used on the mixture of the 
two diastereomers 2.329 and 2.328 and we got only one product 2.352 and the other 
diastereomer 2.328 remain unreacted (scheme 3.43).  
 
 
Reagents and conditions: i. KHMDS/THF/0 
o
C, PhSeCl/0 
o
C – rt; 
Scheme 3.43 
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After the successful preparation of the selenated product 2.352, the aim was to remove 
the PhSe group and form the double bond. We tried using H2O2/THF (scheme 3.44), but 
to no avail, the starting material decomposed and there were unidentifiable products 
formed.  
 
 
Reagents and conditions: i. H2O2/THF/0 
o
C; 
Scheme 3.44 
 
If successful in formation of 2.356, it was more likely to give the required 
stereochemistry for the formation of kainic acid 2.1 (scheme 3.45). 
 
 
Scheme 3.45 
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3.4. Conclusion: 
 
An improved synthesis of oxazolidinone precursor 2.240 has been achieved. Some of 
the steps were improved by using alternative reagents or procedure and the overall yield 
of oxazolidinone 2.240 has been increased. Continuous studies on the stereoselective 
nature of oxazolidinone, gave us a novel unconventional product 2.290.   
 
The procedure in the formation of isoxazole 2.279 was improved compared to previous 
procedures. The formation of enone 2.287, a key intermediate in the Michael addition 
reaction was successfully achieved in higher yield. The diastereomers 2.328 and 2.329 
were successfully synthesised from enone 2.287 by Michael reaction, which could form 
the key intermediates for kainoids. 
 
An attempt to change the stereocenters of C-3 and C-4 positions of diastereomers 2.328 
and 2.329, using different procedures was not successful. Although we were successful 
in the synthesis of selenated product 2.352, we failed to remove the PhSe moiety to 
form the double bond.   
 
We developed a novel route to the total synthesis of allokainic acid 2.2. A formal 
synthesis of allokainic acid involving 11 steps with an overall yield of 9% has been 
reported (scheme 3.46). We have recently published much of this work used to 
synthesise allokainic acid 2.2.
93
  
 
 
  
91 
 
 
Reagents and conditions: i. EtNO2, TsCl, Et3N, benzene, 12h, 68%; ii. (a) Raney Ni, H2, Boric Acid, 
Methanol/Water (5:1), rt; (b) p-TSA·H2O , Toluene , reflux (80
o
C), 89% overall yield; iii. NaH, THF, 
dimethyl malonate, 0 
o
C - rt, 90%, (2.328:2.329 = 1:1); iv. (a) n-BuLi (2.5M), -78 
o
C, Ph3PMeBr/THF, 
(2.338 =72%), (2.329 = 10%). (b) NaCl, DMSO/H2O, 170 
o
C, 83%; 
 
Scheme 3.46
  
 
 
 
 
 
 
 
4. Experimental 
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4.1. General Experimental Procedures 
All experiments were performed under atmosphere of nitrogen unless otherwise stated, 
using oven dried glassware (or flame dried when necessary). Chemical reagents were 
commercially available and used without further purification unless otherwise stated.  
Anhydrous diethyl ether and tetrahydrofuran were distilled from sodium in the presence 
of benzophenone. Dichloromethane, benzene, toluene, N,N-dimethylformamide, 
triethylamine, and ethyl acetate were distilled from calcium hydride prior to use. 
Methanol and ethanol were distilled from activated magnesium turnings using a crystal 
of iodine. Phenyl isocyanate was distilled from P2O5 and stored over flame-dried 3Å 
molecular sieves. All other grade solvents were used as received for routine purposes 
from Fischer scientific. Chemical reagents were commercially available, and used 
without further purification unless otherwise stated.   
All reactions were monitored, where appropriate, by analytical Thin Layer 
Chromatography using Merck glass backed plates pre-coated with 0.25 mm layer of 60 
F254 silica gel. Visualisation was achieved with an Ultra Violet lamp (254 nm), and/or 
by staining with alkaline potassium permanganate, vanillin, or phosphomolybdic acid 
dips. Purification by flash column chromatography was carried according to Still 
procedure,
129
 using Fisher Scientific silica 60A (35-70 mesh) with a pH of 6.5-7.5, 
eluting with solvent commercially available from Fischer scientific. 
Proton nuclear magnetic resonance spectra (
1
H NMR) were recorded using a Varian 
NMR System operating at 500 MHz. Samples were run at ambient probe temperature 
using CDCl3 as the solvent, unless otherwise stated. Residual isotopic solvent (CHCl3, 
δH = 7.27 ppm) was used as the internal reference. Chemical shifts (δ) are measured in 
parts per million (ppm), and coupling constants (J) are measured in Hertz (Hz). The 
following abbreviations are used to represent multiplicity of a given signal: s, singlet; d, 
doublet; t, triplet; m, multiplet; dd, doublet of doublets; ddd, double doublet of doublets; 
dt, doublet of triplets; br, broad singlet. 
Carbon nuclear magnetic resonance spectra (
13
C NMR) were recorded using a Varian 
NMR System operating at 125 MHz. Samples were run at ambient probe temperature 
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using CDCl3 as the solvent, unless otherwise stated. Residual isotopic solvent (CHCl3, 
δC = 77.00 ppm) was used as the internal reference. Chemical shifts (δ) are quoted in 
parts per million (ppm). Carbon spectra assignments are supported by DEPT, HSQC 
and correlation experiments.  
The numbering of all the compounds mentioned in this section is arbitrary, with the sole 
intention to aid in the assignment of protons and carbons in the relevant spectra. They 
do not necessarily correspond with that of the I.U.P.A.C. guidelines. 
Infrared spectra (IR) were recorded on a Perkin-Elmer FT-IR 298 (1710) spectrometer, 
with absorption maxima (νmax) measured in cm
-1
. Some samples were prepared as either 
a thin film (liquids) or a solution in dichloromethane (solids) between sodium chloride 
plates, and other samples were directly placed on a universal attenuated total reflectance 
sampling accessory.  
Low and high resolution mass spectrometry data were recorded by Dr. Alaa Abdul-Sada 
on a Bruker Daltronics Apex III 4.7T using positive electro-spray ionization (+’ve ESI), 
and a Fisons Instrument VG Autospec using positive electron impact (+’ve EI), with 
methanol as the solvent. Only molecular ions, fractions from molecular ions and other 
major peaks are reported as mass/charge (m/z) ratios. The following abbreviations are 
used to describe the experiment: HRMS, high resolution mass spectrometry; LRMS, 
low resolution mass spectrometry. GC MS analyses were carried out on a Quattro micro 
GC using HP-5MS fused silica (30 m × 0.25 i. d. × 0.25 μm). The carried gas used was 
helium at a flow rate of 1 mL/min. 
 
Optical rotations were recorded using a Bellingham-Stanley ADP440 polarimeter with a 
1 cm-path length cell. Optical rotation [α]D data are given in units 10
-1
degcm
2
g
-1
, and 
solution concentrations are given in g/100 cm
-3
.  
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4.2. Total synthesis of platensimycin 1.1 
 
2-bromocyclohex-2-enone 1.19. 
 
 
  
To a stirred solution of 10 mL (98.7 mmol) of 2-cyclohexenone 1.18 in 250 mL of 
DCM at  0 
o
C was added dropwise 5.29 mL (103.2 mmol) of bromine in 100 mL of 
DCM over 30 min. The solution was stirred at 0 
o
C for 1.5 hour, and then 23 mL (165 
mmol) of Et3N was added dropwise. The solution was stirred at room temperature for 
1.5 hour. The solution was washed with two 50 mL portions of 3% HCl and 50 mL of 
saturated brine. After the mixture was dried (using MgSO4) and the solvent evaporated, 
there remained a crude solid. The crude solid was redissolved in DCM, treated with 
activated charcoal, and filtered, and the solvent was removed. Recrystallization from 
EtOAc and hexanes afforded 2-bromocyclohex-2-enone 1.19 as white crystals (12.2 g, 
72%). 
m.p.: 74-75 
o
C. 
1
H NMR (500 MHz, CDCl3): 7.41 (1H, t, J = 6.2, H-3), 2.48-2.59 (2H, m, H-6), 2.37-
3.41 (2H, m, H-4), 2.01-2.09 (2H, m, H-5). 
13
C NMR (125.7 MHz, CDCl3): 190.6 (C-1), 150.3 (C-3), 123.6 (C-2), 38.3 (C-6), 28.1 
(C-4), 22.3 (C-5).   
FTIR vmax cm
-1
 (neat):  1690 (C=O), 1600(C=C). 
HRMS (ESI): m/z calculated for C6H7
79
BrO [M]
+
 = 173.9680, found = 173.9682. 
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2-bromocyclohex-2-enol 1.20. 
 
 
 
To a solution of 3.5 g of 2-bromo-cyclohex-2-enone 1.19 and 7 g of CeCl3·7H2O in 60 
mL of MeOH, 0.78 g of solid NaBH4 was added in small portions over half an hour.  
The mixture was stirred in room temperature for about 30 min. The compound was 
extracted using DCM and dried over anhydrous MgSO4. The 2-bromocyclohex-2-enol 
1.20 formed was colorless oil (2.7 g, 80%). 
 
1
H NMR (500 MHz, CDCl3): 6.21 (1H, t, J = 4.0, H-3), 4.22-4.18 (1H, m, H-1), 2.17 
(1H, d, J = 4.1, OH), 2.08-1.99 (2H, m, H-4), 1.94-1.85 (2H, m, H-6), 1.74-1.64 (2H, m, 
H-5). 
13
C NMR (125.7 MHz, CDCl3): 132.3 (C-3), 125.7 (C-2), 69.9 (C-1), 32.1 (C-6), 27.8 
(C-4), 17.7 (C-5).   
FTIR vmax cm
-1
 (neat): 3361 (OH), 2938, 2866, 2830, 1640 (C=C), 1434, 1331, 1160 
HRMS (ESI): m/z calculated for C6H9BrO [M]
+
 = 175.9837, found = 175.9847. 
 
 
8-methoxy-4-methyl-1,2-dihydronaphthalene 1.31 
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To a solution of CH3MgBr in diethyl ether, 1 g (5.7 mmol) of 5-methoxy-1-tetralone 
1.30 was added in small portions. The mixture was stirred and refluxed for 1 hour. The 
excess of the Grignard reagent was destroyed by slowly adding the mixture to a stirred 
saturated solution of ammonium chloride in water (50 mL). The organic phase was 
separated, dried and evaporated. The crude product obtained was treated with p-TSA 
(45.7 mmol) in toluene. After 30 min two layers were formed. The product was poured 
into 100 mL of water and 50 mL of ether. The organic phase was dried, the solvent was 
evaporated and distilled to obtain 8-methoxy-4-methyl-1,2-dihydronaphthalene 1.31 as 
colorless oil (800 mg, 79%). 
 
1
H NMR (500 MHz, CDCl3): 7.46-7.39 (1H, m, H-6), 6.94-6.88 (1H, m, H-5), 6.85-
6.79 (1H, m, H-7), 5.89-5.82 (1H, m, H-3), 3.83 (3H, s, OCH3), 2.84-2.78 (2H, m, H-1), 
2.26-2.22 (2H, m, H-2), 2.15 (3H, s, CH3). 
13
C NMR (125.7 MHz, CDCl3): 158.1 (C-8), 138.6 (C-10), 135.4 (C-4), 132.5 (C-9),   
128.3 (C-6), 116.3 (C-5), 114.1 (C-3), 112.4 (C-7), 56.3 (OCH3), 26.1 (C-1), 25.2 (C-2), 
19.7 (CH3).  
FTIR vmax cm
-1
(neat): 3054 (C-H), 2926 (C-H), 1573 (C=C), 1460, 1259. 
HRMS (ESI): m/z calculated for C12H14O [M]
+
 = 174.1098, found = 174.1087. 
 
.  
5-methoxy-1-methyl-1,2,3,4-tetrahydronaphthalen-2-ol 1.32. 
 
 
 
200 mg (1.04 mmol) of 8-methoxy-4-methyl-1,2-dihydronaphthalene 1.31 was added to 
20 mL of diethyl ether and to the reaction mixture 1.4 mmol of BH3·THF was added. 
The reaction mixture was stirred at 0 
o
C for 1 h and then at rt for 16 hours. The reaction 
mixture was cooled to 0 
o
C. To the reaction mixture 1 mL of H2O was added and 2 mL 
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of 10% NaOH was added in one portion. Then 2 mL of 35% H2O2 solution was added. 
The reaction mixture was allowed to stir for 20 hours. The crude product was purified 
by column chromatography using 25% ether-petrol as solvent phase. After removal of 
the solvent 5-methoxy-1-methyl-1,2,3,4-tetrahydronaphthalen-2-ol 1.32 was crystallized 
using ethyl acetate and methanol (160 mg, 71%). The X-Ray crystallographic studies 
confirmed the structure (figure 1.3). 
 
1
H NMR (500 MHz, CDCl3): 6.81-6.75 (1H, m, H-7), 6.54-6.49 (1H, m, H-8), 6.47-
6.44 (1H, m, H-6), 3.85 (3H, s, OCH3), 3.55 (1H, s, OH), 3.35-3.31 (1H, m, H-2), 3.13-
3.09 (1H, m, H-1), 2.87-2.83 (2H, m, H-4), 1.84-1.79 (2H, m, H-3), 1.22 (2H, s, CH3). 
13
C NMR (125.7 MHz, CDCl3): 157.2 (C-5), 136.7 (C-9), 126.8 (C-7), 126.1 (C-10), 
117.8 (C-8), 108.9 (C-6), 70.9 (C-2), 56.2 (OCH3), 40.2 (C-1), 28.4 (C-3), 18.9 (C-4), 
16.9 (CH3). 
HRMS (ESI): m/z calculated for C12H16O2Na [M
+
Na]
+
 = 215.1058, found = 215.1074. 
 
 
 
tert-butyl(5-methoxy-1-methyl-1,2,3,4-tetrahydronaphthalen-2-
yloxy)dimethylsilane 1.27 
 
 
 
To a stirred solution of 5-methoxy-1-methyl-1,2,3,4-tetrahydronaphthalen-2-ol 1.32 
(100 mg, 0.33 mmol) in dry DCM (10 mL) at 0 ºC was added tert-butyldimethylsilyl 
chloride (58 mg, 0.39 mmol) and imidazole (56 mg, 0.82 mmol). After 1 hour, the 
reaction mixture was quenched with water. The phases were separated and the aqueous 
phase was extracted twice with DCM. The organic layers were combined, washed once 
with water, washed once with brine, dried over anhydrous sodium sulphate and 
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concentrated under reduced pressure to give a colourless liquid. Distillation under 
reduced pressure afforded tert-butyl(5-methoxy-1-methyl-1,2,3,4-tetrahydronaphthalen-
2-yloxy)dimethylsilane 1.27 as brown oil (127 mg 80%). 
 
1
H NMR (500 MHz, CDCl3): 6.83-6.78 (1H, t, H-7), 6.51-6.48 (1H, m, H-8), 6.46-6.42 
(1H, m, H-6), 3.83 (3H, s, OCH3), 3.33-3.29 (1H, m, H-2), 3.11-3.08 (1H, m, H-1), 
2.89-2.82 (2H, m, H-4), 1.86-1.83 (2H, m, H-3), 1.24 (2H, s, CH3), 0.97 (9H, s, 
SiC(CH3)3), 0.20 (6H, s, Si(CH3)2). 
13
C NMR (125.7 MHz, CDCl3): 157.4 (C-5), 136.9 (C-9), 126.8 (C-7), 126.1 (C-10), 
117.9 (C-8), 109.1 (C-6), 83.5 (C-2), 56.1 (OCH3), 41.5 (C-1), 30.8 (C-11), 29.5 (C-3), 
26.0 (SiC(CH3)3), 19.1 (C-4), 16.6 (CH3). 
Ion not found. 
 
4.3. Synthesis of oxazolidinone 2.240 
 
(2S,4R)-methyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride 2.235 
 
 
 
The title compound was prepared by a modification of the procedure of Jason Lai.
96 
To a stirred suspension of trans-4-hydroxy-L-proline 2.234 (10.0 g, 76.0 mmol) in 
methanol (40 mL), thionyl chloride (2.49 mL, 34.31 mmol) was added drop wise at       
0 
o
C. The reaction mixture was stirred at 0 
o
C for 1 hour before being heated at reflux 
for 24 hours, and re-cooled to 0 
o
C. The mixture was diluted with diethyl ether (80 mL). 
The white precipitate obtained was filtered, washed with diethyl ether (2 x 20 mL) and 
dried under reduced pressure to give methyl (4R)-4-hydroxy-L-prolinate hydrochloride 
2.235 as a white solid (11.5 g, 83%). 
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1H NMR (500 MHz, DMSO) δ (Doubling and broad peaks as a result of rotamers): 4.46 
(1H, dd, J = 10.6 and 7.6, H-2), 4.38 (1H, m, H-4), 3.74 (3H, m, H-7), 3.33-3.06 (2H, 
(3.06 (d, J =12.1, 1H)), H-5), 2.17-2.06 (2H, m, 3-H). 
13
C NMR (126 MHz, DMSO) δ (Doubling and broad peaks as a result of rotamers): 
169.4 (C-6), 68.9 (C-4), 58 (C-2), 53.6 (C-7), 53.4 (C-5), 37.5 (C-3). 
FTIR υmax cm
-1
(neat): 3321 (sharp, OH-free), 1739 (C=O of ester). 
HRMS (ESI): m/z calculated for C6H12NO3 [M]
+
  =
 
146.0812, found = 146.0811. 
  
 
(2S,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 2.236 
 
 
 
The title compound was prepared by a modification of the procedure of Jason Lai.
96
 
Diisopropylethylamine (57.5 mL, 330.34 mmol) and di-tert-butyl dicarbonate (63.0 g, 
289.24 mmol) were added to a suspension of (2S,4R)-methyl 4-hydroxypyrrolidine-2-
carboxylate hydrochloride 2.235 (50 g, 342.2 mmol) in DCM (500 mL) at 0 
o
C. The 
reaction mixture was allowed to warm to room temperature and stirred for 24 hours 
before being concentrated under reduced pressure. The residue formed was diluted with 
ethyl acetate (250 mL), and saturated ammonium chloride solution (250 mL) was added. 
The aqueous phase was further extracted with ethyl acetate (3 x 300 mL). The organic 
phases were combined, and washed with saturated sodium hydrogen carbonate (1000 
mL), brine (1000 mL), and dried over magnesium sulfate. The resultant solution was 
concentrated under reduced pressure to give (2S,4R)-1-tert-butyl 2-methyl 4-
hydroxypyrrolidine-1,2-dicarboxylate 2.236 as a yellow oil (58.3 g, 86.3%). This was 
used without any further purification. 
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1
H NMR (500MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers): 4.48 
(1H, m, H-4), 4.39 (1H, t, J = 7.9, H-2), 3.72(3H, s, H-10), 3.63-3.44 (2H, m, H-5), 2.28 
(1H, m, H-4), 2.08 (2H, m, H-3), 1.43 (9H, 2s, H-9). 
13
C NMR (126 MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers): 
173.6 (C-6), 154.0 (C-7), 80.4 and 80.3 (C-8), 70 and 69.3 (C-4), 57.9 and 57.4 (C-2), 
54.6 (C-5), 52.8 (C-10), 39.1 and 38.4 (C-3), 28.3 and 28.2 (C-9). 
FTIR υmax cm
-1
(neat): 3322 (O-H  sharp, OH free), 1740 (C=O). 
HRMS (ESI+): m/z calculated for C11H19NO5Na [M+Na]
+ 
= 268.1155 found = 
268.1154. 
Spectroscopic data identical to literature values.
95,96 
 
 
(2S,4R)-1-tert-butyl 2-methyl 4-(methylsulfonyloxy)pyrrolidine-1,2-dicarboxylate 
2.241. 
 
 
 
The title compound was prepared by a modification of the procedure of Jason Lai.
96
 
Methanesulfonyl chloride (21.5 g, 188.2 mmol) and 4-dimethylaminopyridine (2.1 g, 
17.1 mmol) were added to a stirred solution of 1-tert-butyl 2-methyl (2S ,4R)-4-
hydroxypyrrolidine-1,2-dicarboxylate 2.236 (41.9 g, 171.11 mmol) and triethylamine 
(25.7 mL, 184.8 mmol) in DCM (600 mL) at 0 
o
C. The reaction mixture was stirred and 
allowed to warm to room temperature for 15 hours before cooling to 0 
o
C and adding 
water (300 mL). The phases were separated and the aqueous phase was extracted with 
DCM (3 x 200 mL). The organic extracts were combined and washed with 1M citric 
101 
 
acid solution, saturated sodium hydrogen carbonate solution and dried over magnesium 
sulfate. The extract was concentrated under reduced pressure. The crude product 
obtained was purified by flash column chromatography on silica gel, eluting with 50% 
ethylacetate / petrol gave 1-tert-butyl 2-methyl(2S,4R)-4-
[(methylsulfonyl)oxy]pyrrolidine-1,2-dicarboxylate 2.241 as a white solid (45.4 g, 
82%). This was used without any further purification. 
1H NMR (500 MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers): 5.28 
(1H, m, H-4), 4.45 (1H, dt, J = 33.9 and 7.9, H-2), 3.86-3.78 (2H, m, H-5), 3.76 (3H, s, 
H-10), 3.06 (3H, s, H-11), 2.66-2.57 (1H, m, H-3), 2.27 (1H, m, H-3), 1.47-1.44 (9H, 2 
x s, H-9). 
 
13C NMR (126 MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers):  
172.9 (C-6), 153.5 (C-7), 80.8 (C-8), 77.9 (C-4), 57.5 (C-2), 52.5 (C-10), 52.3 (C-5), 
38.8 (C-11), 37.5 (C-3), 28.4 (C-9). 
 
FTIR    υmax cm
-1
(neat): 2972 (O-SO2CH3 , 1745 (C=O), 1696 (C=O). 
HRMS (ESI+): m/z calculated for C12H21NO7SNa [M+Na]
+ 
= 346.0931 found = 
346.0928.  
Spectroscopic data identical to literature values.
95,96 
 
 
(2S,4S)-1-tert-butyl 2-ethyl 4-(phenylselanyl)pyrrolidine-1,2-dicarboxylate 2.242 
 
 
 
The title compound was prepared by a modification of the procedure of Jason Lai.
96
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Sodium borohydride (6.35 g, 167.8 mmol) was added to a stirred suspension of 
diphenyl diselenide (22.9 g, 76.9 mmol) in anhydrous ethanol (750 mL) at 0 
o
C portion 
wise. The reaction mixture was allowed to warm to room temperature and stirred for 
one hour    before re-cooling to 0 
o
C. The solution of 1-tert-butyl 2-methyl (2S,4R)-4-
[(methylsulfonyl)oxy]pyrrolidine-1,2-dicarboxylate 2.241 (45.2 g, 139.9mmol) in 
anhydrous ethanol (250 mL) was added to the reaction mixture followed by heating at 
reflux for 24 hours. The reaction mixture was concentrated under reduced pressure, re-
diluted with diethyl ether (1000 mL) and washed with water (600 mL). The phases were 
separated and the aqueous phase was extracted with diethyl ether (3 x 500 mL). The 
organic phases were combined and further washed with saturated sodium chloride 
solution (600 mL), dried over magnesium sulphate and concentrated under reduced 
pressure to give the crude (2S,4S)-1-tert-butyl 2-ethyl 4-(phenylselanyl)pyrrolidine-1,2-
dicarboxylate 2.242 as a brown oil (51.5 g, 92%). This compound was not isolated. This 
was used without any further purification. 
 
 
(2S)-1-tert-butyl 2-methyl 4-iodopyrrolidine-1,2-dicarboxylate 2.237. 
 
 
 
(2S,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 2.236, 500 mg 
(1.9 mmol) was dissolved using stirring and a little heat in toluene (5 mL) and 
acetonitrile (3 mL). The mixture was cooled to 0 
o
C, and triphenyl phosphine (1.57 g, 
6mmol), imidazole (0.82 g, 12.1 mmol) and iodine (1.58 g 6.2 mmol) were added. After 
24 hours, the mixture was filtered and the filtrate was reduced under low pressure. 
Diethyl ether (5 mL) was added to precipitate remaining triphenylphophine oxide which 
was removed by filtration. Residual iodine was removed from the filtrate by washing 
with sodiumthiosulfate (5 mL). The organic layer was reduced at low pressure and the 
iodinated pyrrolidine 2.237 was purified by flash chromatography, starting with 100% 
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hexane and then 2:1 ethyl acetate and hexane to give (2S)-1-tert-butyl 2-methyl 4-
iodopyrrolidine-1,2-dicarboxylate 2.237 as a mixture of white crystalline solid and 
yellow oil (620 mg, 88%). 
 
1
H NMR (500MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers): 4.46-
4.32 (1H, m, H-4), 4.06 (1H, m, H-2), 3.90-3.71 (2H, m, H-5), 3.74 (3H, s, H-10), 2.56-
2.39 (2H, m, H-3), 1.43-1.40 (9H, 3xs, H-9). 
13C NMR (126 MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers): 
172.8(C-6), 153.2(C-7), 80.6(C-8), 58.7 (C-4), 58.5(C-2), 57.4 (C-5), 52.3 (C-10), 42.6 
(C-3), 28.4 (C-9). 
FTIR υmax cm
-1
(neat): 1698.69 (C=O). 
HRMS (ESI+): m/z calculated for C11H18INO4Na [M+Na]
+ 
= 378.0173 found = 
378.0187. 
 
 
(S)-1-tert-butyl 2-methyl 1H-pyrrole-1,2(2H,5H)-dicarboxylate 2.238. 
 
 
 
DBU (0.22 g, 1.4 mmol) was added to a flask containing a stirring solution of toluene       
(5 mL) and (2S)-1-tert-butyl 2-methyl 4-iodopyrrolidine-1,2-dicarboxylate 2.237 
(500mg, 1.3 mmol). The mixture was stirred and heated to 85 
o
C for over 7 hours to 
give a white precipitate. The reaction mixture was filtered to remove the shining white 
powder and the filtrate was concentrated under reduced pressure to give a crude orange 
oil. The oil was purified by flash chromatography using 1:20 ethyl acetate and hexane 
and slowly increasing to 1:1 to give (S)-1-tert-butyl 2-methyl 1H-pyrrole-1,2(2H,5H)-
dicarboxylate 2.238 as yellow oil (250 mg, 75%). 
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1
H NMR (500MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers): 6.02-
5.89 (1H, m, H-4), 5.78-5.71 (1H, m, H-3), 5.06-4.92 (1H, m, H-2), 4.32-4.14 (2H, m, 
H-5), 3.75 (3H, s, H-10), 1.48 and 1.43 (9H, 2 x s, H-9) 
13
C NMR (126 MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers): 
171.0(C-6), 153.1(C-7), 129.3 and 129.2 (C-4), 124.7 and 124.6 (C-3), 80.1 and 80.09 
(C-8), 66.5 and 66.1 (C-2), 53.4 and 53.2 (C-10), 52.5 and 52.07(C-5),  28.3 and 28.2 
(C-9).  
FTIR υmax cm
-1
(neat): 2986 (=C-H st), 1704 (C=O). 
HRMS (ESI+): m/z calculated for C11H17NO4Na [M+Na]
+ 
= 250.1050 found = 
250.1047. 
Spectroscopic data identical to literature values.
95,96 
 
 
(S)-tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate 2.239. 
 
 
 
The title compound was prepared by a modification of the procedure of Jason Lai.
96
 
(S)-1-tert-butyl 2-methyl 1H-pyrrole-1,2(2H,5H)-dicarboxylate 2.238 (2 g, 8 mmol), 
was dissolved in a mixture of THF (18 mL) and anhydrous methanol (9 mL). The 
solution was cooled to 0 
o
C. Sodium Borohydride (1 g, 26.4 mmol) was added via a 
solid addition tube over an hour. The reaction was gradually warmed to room 
temperature and was allowed to stir overnight. The reaction mixture was again cooled to 
0 
o
C and a saturated ammonium chloride solution was added drop wise. The solvents 
were removed under reduced pressure. The remaining aqueous phase was filtered 
through Celite® and washed with ethyl acetate. The layers were separated and the 
aqueous phase was extracted with ethyl acetate and organic fractions were dried over 
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magnesium sulphate. The solvents were removed under reduced pressure to give (S)-
tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate 2.239 as an viscous 
orange oil (1.52 g, 85%). 
1
H NMR (500 MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers): 5.93-
5.81(1H, m, H-4), 5.69-5.62(1H, m, H-3), 4.74-4.58(1H, m, H-2), 4.58(1H, s, OH), 
4.18(1H, d, J = 15.7, H-5), 4.12-4.06(1H, m, H-5), 3.78(1H, t, J = 9.4, H-6), 3.60-
3.54(1H, m, H-6), 1.50(9H, s, H-9). 
13
C NMR (126 MHz, CDCl3) δ (Doubling and broad peaks as a result of rotamers): 
156.5 (C-7), 126.7 (C-3), 126.67 ( C-4), 80.5 (C-8), 67.6 (C-2), 67.1 (C-5), 54.1 (C-6), 
28.4 (C-9). 
FTIR υmax cm
-1
(neat): 3432 (O-H broad, H-bonded), 2982 (=C-H st), 1673 (C=O). 
HRMS (ESI+): m/z calculated for C10H17NO3Na [M+Na]
+ 
= 222.1101 found = 
222.1095. 
Spectroscopic data identical to literature values.
95,96 
 
 
 (S)-1,7a-dihydropyrrolo[1,2-c]oxazol-3(5H)-one 2.240. 
 
 
 
The title compound was prepared by a modification of the procedure of Jason Lai.
96
 
To a flask containing (S)-tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-
carboxylate 2.239 (5.69 g, 25.6 mmol) in anhydrous DCM (100 mL) flushed with N2 
gas and cooled to 0 
o
C, DAST was added(4.59 mL in 25 mL DCM  28.5 mmol) 
dropwise over an hour. The mixture was allowed to warm to room temperature and 
stirred for nearly 16 hrs before cooling again to 0 
o
C. To this reaction mixture aqueous 
sodium bicarbonate (70 mL) was added slowly. The layers were separated and the 
aqueous phase was extracted with DCM (3 x 100 mL). The combined organic fractions 
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were washed with ammonium chloride (100 mL) and dried with magnesium sulfate. 
The resultant organic fraction was concentrated under reduced pressure. This was 
purified by flash chromatography using 7:1 ether, hexane to give (S)-1,7a-
dihydropyrrolo[1,2-c]oxazol-3(5H)-one 2.240 as a brown oil (3.1 g, 86%). 
1
H NMR (500 MHz): 6.06-6.04 (1H, m, H-7), 5.91-5.90 (1H, m, H-6), 4.75-4.70 (1H, 
m, H-5), 4.60 (1H, t, J = 8.7, H-4), 4.42-4.38 (1H, m , H-8), 4.24 (1H, dd, J = 8.6, 5.1, 
H-4), 3.84-3.80 (1H, m, 8-H). 
13
C NMR( 125.7 MHz, CDCl3): 163.3 (C-2), 130.9 (C-7), 128.9 (C-6), 68.7 (C-4), 64.6 
(C-5), 54.8 (C-8). 
FTIR υmax cm
-1
 (neat): 2920 (=C-H st), 1738 (C=O). 
HRMS (ESI+): m/z calculated for C6H7NO2Na [M+Na]
+ 
= 148.0369 found = 148.0816. 
Spectroscopic data identical to literature values.
95,96 
 
 
4.4. Synthesis of enone 2.287. 
 
  (Z)-6-(1-(methoxyimino)ethyl)tetrahydropyrrolo[1,2-c]oxazol-3(1H)-one 2.279. 
 
 
 
The title compound was prepared by a modification of the procedure of Jason Lai.
96
 
Triethylamine (162 mg, 1.6 mmol) was added to a stirred solution of (S)-1,7a-
dihydropyrrolo[1,2-c]oxazol-3(5H)-one 2.240 (100 mg, 0.8 mmol), nitroethane (72 mg, 
0.96 mmol) and p-toluene sulphonyl chloride (305 mg, 1.6 mmol) in benzene (20 mL) 
at 0 
o
C. The reaction mixture was allowed to warm to room temperature and left to stir 
for 12 hours. The solvents were removed  under reduced pressure and further purified 
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using flash chromatography using 1:1 hexane and ethyl acetate, followed by neat ethyl 
acetate to give (Z)-6-(1-(methoxyimino)ethyl)tetrahydropyrrolo[1,2-c]oxazol-3(1H)-one 
2.279 as a white crystalline solid (98 mg, 68%). The X-Ray crystallographic studies 
confirmed the structure (figure 3.7). 
TLC, Rf = 0.36. (100% EtOAc). 
m.p.: 123.1-127.4 
o
C. 
[α]D -1.66° (c 1.0, CH2Cl2). 
1
H NMR (500 MHz) : 5.06 (1H, dd, J = 8.5, 4.8, H-6), 4.69 (1H, dd, J = 8.9, 2.6, H-4), 
4.48 (1H, t, J = 8.6, H-4), 4.06 (1H, m, H-12), 4.05 (1H, m, H-5), 3.82 (1H, t, J = 8.1, 
H-11), 3.27 (1H, dd, J = 12.9, 7.6 Hz, H-12). 
13
C NMR (125.7 MHz, CDCl3):  176.9 (C-2), 155.1 (C-9), 83.6 (C-6), 64.3 (C-4), 62.6 
(C-5), 58.1 (C-11), 48.0 (C-12), 11.3 (C-10). 
FTIR υmax cm
-1
(neat): 2922 (=C-H st), 1737 (C=O), 1462 (CH2), 1191 (C-O), 993 (N-
O), 777. 
HRMS (ESI+): m/z calculated for C8H10N2O3Na [M+Na]
+ 
= 205.0583 found = 205.0584 
Spectroscopic data identical to literature values.
96 
 
 
(6S,7S)-7-chloro-3-oxohexahydropyrrolo[1,2-c]oxazol-6-yl 4-
methylbenzenesulfonate 2.290 
 
 
 
During the preparation of 2.279, the solvent benzene was replaced with DCM, and 
under the same reagents and conditions used for the preparation of 2.279, the byproduct 
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(6S,7S)-7-chloro-3-oxohexahydropyrrolo[1,2-c]oxazol-6-yl 4-methylbenzenesulfonate 
2.290 was  isolated as a crystalline solid (1 g, 15%). The X-Ray crystallographic studies 
confirmed the structure (figure 3.5). 
TLC, (EtOAc) Rf = 0.35. 
m.p.: 148.1-149.5 
o
C. 
[α]D +3.78° (c 1.0, CHCl3). 
1
H NMR (500 MHz, CDCl3) δ: 7.81 (2H, d, J = 8.3, H-10), 7.41 (2H, d, J = 8.4, H-11), 5.12 
(1H, d, J = 5.3, H-7), 4.59-4.55 (1H, m, H-4), 4.48 (1H, dd, J = 9.5, 2.7, H-4), 4.45 (1H, dt,  J= 
8.3, 2.9, H-6), 4.38 (1H, d,  J= 3.1, H-5)  4.02 (1H, dd, J = 13.5, 5.3, H-13), 3.2 (1H, d, J = 13.5, 
H-8).  
13
C NMR( 125.7 MHz, CDCl3) δ: 160.7 (C-2), 146.1 (C-8), 132.5 (C-12), 130.4 (2C, C-
10), 127.9 (2C, C-11),  84.8 (C-7), 63.6 (C-4), 61.6 (C-6), 61.3 (C-5), 50.40 (C-8), 21.7 
(C-13). 
FTIR    υmax cm
-1
(neat): 2978 (O-SO2-Ph) , 1749 (C=O). 
HRMS (ESI+): m/z calculated for C13H14ClNO5SNa [M+Na]
+
 = 354.0173 found = 
354.0174.  
 
 
1-(2,5-dihydro-1H-pyrrol-1-yl)-2,2,2-trifluoroethanone 2.302. 
 
 
 
The title compound was prepared by the modification procedure described by Carl B Ziegler.
130
 
3-pyrroline (10 g, 144.9 mmol) was dissolved in a mixture of pyridine (15 mL) and 
diethyl ether (30 mL) and to the reaction mixture trifluoroacetic anhydride (22 mL) was 
added dropwise over a period of 1 hour. The reaction mixture was stirred at room 
temperature for an additional hour and the pyridiniumtrifluoroacetate salt obtained was 
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removed by filteration. The filtrate was evaporated to an oily residue which was 
distilled (36
o
C
 
/3.5- mmHg) to give 1-(2,5-dihydro-1H-pyrrol-1-yl)-2,2,2-
trifluoroethanone 2.302 as deep blue coloured oil (14 g, 61%). 
1
H NMR (500 MHz, CDCl3) δ:  5.90 - 5.83 (2H, m, H-3 and H-4), 4.47 - 4.36 (4H, m, 
H-2 and H-5).  
13
C NMR( 125.7 MHz, CDCl3) δ: 155.3 (C-6), 124.8 and 124.6 (C-3 and C-4), 117.4 
and 115.1 (C-7), 54.6 and 53.0 (C-2 and C-5). 
FTIR    υmax cm
-1
(neat): 1688 (C=O), 1462 (CH2), 1133 (C-C). 
HRMS (ESI+): m/z calculated for C6H6NONa [M+Na]
+
 = 188.0294 found =188.0292. 
 
 
(6R,7R)-6-acetyl-7-hydroxytetrahydropyrrolo[1,2-c]oxazol-3(1H)-one 2.288. 
 
 
 
Raney®-nickel (10-20 mg) was added to the (Z)-6-(1-
(methoxyimino)ethyl)tetrahydropyrrolo[1,2-c]oxazol-3(1H)-one 2.279 (680 mg, 3.7 
mmol) and boric acid (485 mg, 7.8 mmol), in 5:1 mixture of methanol and water (30 
mL). The reaction mixture was allowed to stir for 8 h under hydrogen atmosphere. The 
Raney®-nickel was removed by filtration using Celite®. The solvent was removed 
under reduced pressure and the product (6R,7R)-6-acetyl-7-
hydroxytetrahydropyrrolo[1,2-c]oxazol-3(1H)-one 2.288 was used in next step without 
further purification. This compound was not isolated. 
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(S)-6-acetyl-1,7a-dihydropyrrolo[1,2-c]oxazol-3(5H)-one 2.287. 
 
 
 
To a flask containing (6R,7R)-6-acetyl-7-hydroxytetrahydropyrrolo[1,2-c]oxazol-3(1H)-
one 2.288  in toluene, a catalytic amount of p-TSA·H2O (3 mg) was added and refluxed 
using Dean-Stark apparatus for 8 h. After 8 h, the product in toluene was extracted 
using DCM and concentrated under reduced pressure. The resultant crude was further 
purified using flash chromatography with 9:1 ethyl acetate and hexane to give (S)-6-
acetyl-1,7a-dihydropyrrolo[1,2-c]oxazol-3(5H)-one 2.287 as brown solid (560 mg, 
89%). The X-Ray crystallographic studies confirmed the structure (figure 3.4). 
TLC, (EtOAc) Rf = 0.40. 
m.p.: 76.9-78.7 
o
C. 
[α]D -0.9° (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ: 6.66 (1H, dd, J = 3.6, 1.7, H-6), 4.96-4.89 (1H, m, H-5), 
4.67 (1H, t, J = 9.0, H-4), 4.62 (1H, ddd, J = 15.7, 2.9, 1.6, H-8), 4.36 (1H, dd,   J = 8.9, 
4.9, H-4), 4.02 (1H, ddd, J = 15.8, 4.7, 2.4, H-8), 2.38 (3H, s, H-10). 
13
C NMR (125.7 MHz, CDCl3) δ: 193.9 (C-9), 162.5 (C-2), 145.1 (C-7), 138.0 (C-6), 
67.4 (C-4), 65.4 (C-5), 53.6 (C-8), 27.0 (C-10). 
FTIR    υmax cm
-1
(neat): 2922 (=C of enone), 1733 (C=O of oxazolidinone ring), 1671 
(C=O of enone), 1185 (C-O), 1006 ( H3C-N), 775. 
HRMS (ESI+): m/z calculated for C8H9NO3Na [M+Na]
+
 = 190.0475 found =190.0478.                            
Spectroscopic data identical to literature values.
96 
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4.5. Formal synthesis of allokainic acid 2.2 and epikainate 
2.346. 
 
Dimethyl 2-((6R,7S,7aS)-6-acetyl-3-oxohexahydropyrrolo[1,2-c]oxazol-7-
yl)malonate 2.329 
 
 
 
To a suspension of sodium hydride (60 % dispersion in oil, 0.51 g, 8.5 mmol) in THF 
(40 mL), a solution of dimethyl malonate (1.12 g, 8.5 mmol) in THF (15 mL) was 
added. The reaction mixture was stirred at room temperature for 2 h, then a solution of 
(S)-6-acetyl-1,7a-dihydropyrrolo[1,2-c]oxazol-3(5H)-one 2.287, (1.42 g, 8.5 mmol) in 
THF (15 mL) was added dropwise at 0 °C. The mixture was left to stir overnight at 
room temperature. The reaction was quenched with a saturated ammonium chloride 
solution (20 mL) and extracted with diethyl ether (5 x 30 mL). The combined organic 
phases were washed with brine (20 mL), dried over magnesium sulfate and the solvent 
was removed under reduced pressure. The resultant residue obtained was purified using 
flash column chromatography (hexanes/ethyl acetate : 7/3) to yield the dicarboxylates 
2.329 and 2.328 as a mixture of two isomers in 1:1 ratio, as a pale yellow solid (2.33 g, 
90 %). The X-Ray crystallographic studies confirmed the structure (figure 3.8). 
TLC, (EtOAc) Rf = 0.88. 
m.p.: 117.5-127.2 
o
C 
[α]D -2.5° (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ: 4.53-4.47 (1H, m, H-5), 4.44-4.40 (1H, m, H-4), 4.33 
(1H, dd, J = 11.7, 6.3, H-4), 4.04-3.99 (1H, m, H-9), 3.91 (1H, t, J = 8.4, H-8), 3.74 
112 
 
(6H, 2 x s, H-11 and H-13), 3.29 (1H, m, H-6), 3.26 (1H, m, H-8), 3.04 (1H, m, H-7), 
2.21 (3H, s, H-15). 
13
C NMR (125.7 MHz, CDCl3) δ: 208.6 (C-14), 169.0 and 168.9 (C-10 and C-12), 
161.3 (C-2), 65.5 (C-4), 58.1 (C-5), 53.0 and 52.9 (C-11 and C-13), 52.1 (C-6), 49.2 (C-
8), 48.0 (C-9), 43.9 (C-7), 30.0 (C-15). 
FTIR    υmax cm
-1
(neat): 2929 (CH3), 1732 (C=O of lactone), 1728 (C=O of ester) 1680  
(C=O of ketone), 1436 (CH2), 1248 (C-N), 1154, 767. 
HRMS (ESI+): m/z calculated for C13H17NO7Na [M+Na]
+
 = 322.0897 found = 
322.0893.    
 
Dimethyl 2-((6S,7R,7aS)-6-acetyl-3-oxohexahydropyrrolo[1,2-c]oxazol-7-
yl)malonate 2.328 
 
 
 
TLC, (EtOAc) Rf = 0.74. 
m.p.: 118.3-128.3 
o
C 
[α]D -0.9° (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ: 4.44-4.41 (1H, m, H-4), 4.41-4.38 (1H, m, H-5), 4.11-
4.08 (1H, m, H-8), 4.07-4.02 (1H, m, H-4), 3.77 and 3.72 (6H, 2 x s, H-11 and H-13), 
3.48-3.45 (1H, m, H-9), 3.38-3.33 (1H, m, H-6), 3.33-3.29 (1H, m, H-7), 3.06-3.01 (1H, 
m, H-8), 2.22 (3H, s, H-15). 
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13
C NMR (125.7 MHz, CDCl3) δ: 205.6 (C-14), 168.5 and 168.2 (C-10 and C-12), 
160.2 (C-2), 64.2 (C-4), 60.0 (C-5), 55.2 (C-7), 53.2 (C-11 and C-13), 51.3 (C-9), 48.3 
(C-8), 42.2 (C-6), 29.9 (C-15). 
FTIR υmax cm
-1
(neat): 2959 (CH3), 1737 (C=O of lactone),1730 (C=O of ester) 1701       
(C=O of ketone), 1432 (CH2), 1273 (C-N), 1020, 769.. 
HRMS (ESI+): m/z calculated for C13H17NO7Na [M+Na]
+
 = 322.0897 found = 
322.0906.                                                                                                                                                                                                                                                                                                                                 
 
 
Dimethyl 2-((6S,7S,7aS)-3-oxo-6-(prop-1-en-2-yl)hexahydropyrrolo[1,2-c]oxazol-7-
yl)malonate 2.343 
 
 
 
The olefination was performed by a modification of the procedure of Hanessian.
53
 
n-BuLi in hexane (2.5 M, 2.84 mL) was added at -78 °C to a suspension of Ph3PMeBr 
(12.03 g, 33.6 mmol) in THF (30 mL). The mixture was stirred at room temperature for 
20 min and then brought to -60 °C prior to the addition of a solution of dimethyl 2-
((6R,7S,7aS)-6-acetyl-3-oxohexahydropyrrolo[1,2-c]oxazol-7-yl)malonate 2.329, (0.85 
g) in THF (20 mL). The reaction mixture was kept at -60 °C for 1 h and warmed to 25 
°C over a period of 0.5 h. The reaction mixture was filtered over Celite®-silica gel, and 
the remaining solvent was removed under reduced pressure and the resulting residue 
was subjected to flash column chromatography on silica, eluting with (60% ethyl 
acetate in hexane) to afford 2.343 as a white solid (0.69 g, 81%). 
TLC, (EtOAc/Hexane: 2/5) Rf = 0.70. 
m.p.: 105.7-108.3 
o
C 
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[α]D -2.1° (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ: 4.90-4.86 (1H, m, H-16), 4.81 (1H, s, H-16), 4.54 (1H, 
td, J = 8.8, 5.2, H-5), 4.41 (1H, dd, J = 9.9, 8.8, H-4), 3.94 (1H, dd, J = 10.0, 5.2, H-4), 
3.87 (1H, dd, J = 12.0, 7.2, H-8), 3.76 and 3.65 (6H, 2 x s, H-11 and H-13), 3.40 (1H, d, 
J = 11.1 , H-9), 3.04-2.97 (1H, m, H-6), 2.97-2.91 (1H, m, H-8), 2.56 (1H, td, J = 9.9, 
7.4, H-7), 1.71 (3H, s, H-15).                                                                                                                                                                                                                                                                                                          
13
C NMR (125.7 MHz, CDCl3) δ: 168.9 and 167.9 (C-10 and C-12), 160.9 (C-2), 141.1 
(C-14), 114.5 (C-16), 64.9 (C-4), 60.0 (C-5), 53.1 and 52.4 (C-11 and C-13), 52.3 (C-9), 
51.5 (C-7), 50.9 (C-8), 42.7 (C-6), 18.8 (C-15). 
FTIR υmax cm
-1
(neat): 2962 (CH3), 2929 (=CH2), 2030 (C=C, alkene), 1728 ( -C=O- of 
lactone), 1690 ( C=O, ester), 1440 (CH2), 1243 (C-N), 1150, 1008, 923. 
HRMS (ESI+): m/z calculated for C14H19NO6Na [M+Na]
+
 = 320.1105 found = 
320.1102.   
 
 
Dimethyl 2-((6R,7R,7aS)-3-oxo-6-(prop-1-en-2-yl)hexahydropyrrolo[1,2-c]oxazol-
7-yl)malonate 2.338 
 
 
 
The olefination was performed by a modification of the procedure of Hanessian.
53 
n-BuLi in hexane (2.5 M, 2.84 mL) was added at -78 °C to a suspension of Ph3PMeBr 
(12.03 g, 33.6 mmol) in THF (30 mL). The mixture was stirred at room temperature for 
20 min and then brought to -60 °C prior to the addition of a solution of dimethyl 2-
((6S,7R,7aS)-6-acetyl-3-oxohexahydropyrrolo[1,2-c]oxazol-7-yl)malonate 2.328, (0.85 
g) in THF (20 mL). The reaction mixture was kept at -60 °C for 1 h and warmed to 25 
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°C over a period of 0.5 h. The reaction mixture was filtered over Celite-silica gel, and 
the remaining solvent was removed under reduced pressure. The residue obtained was 
subjected to flash column chromatography on silica, eluting with (60% ethyl acetate in 
hexane) to afford 2.338 as a white solid (0.61 g, 72%). The compound 2.329 was 
formed as byproduct (0.07 g, 10%). 
TLC, (EtOAc/Hexane: 2/5) Rf = 0.65. 
m.p.: 106.5-109.8 
o
C
 
 
[α]D -1.28 ° (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ: 4.85-4.82 (1H, m, H-16), 4.81 (1H, s, H-16), 4.51 (1H, 
dd, J = 9.5, 8.0, H-4), 4.45-4.40 (1H, m, H-4), 4.05 (1H, td, J = 8.5, 4.3, H-5), 3.75-3.69 
(6H, 2 x s, H-11 and H-13), 3.54-3.49 (1H, m, H-8), 3.49-3.46 (1H, m, H-9), 3.37 (1H, 
dd, J = 11.6, 9.4, H-8), 2.96 (1H, dd, J = 17.1, 9.4, H-6), 2.43 (1H, dt, J = 16.8, 8.5, H-
7),  1.68 (3H, s, H-15).                                                                                                                                                                                                                                                                                                          
13
C NMR (125.7 MHz, CDCl3) δ: 168.1 (C-10 and C-12), 160.3 (C-2), 141.8 (C-14), 
114.7 (C-16), 68.2 (C-4), 62.2 (C-5), 53.2 (C-6),52.8 and 52.5 (C-11 and C-13), 52.3 
(C-9), 48.5 (C-8), 45.8 (C-7), 17.7 (C-15). 
FTIR υmax cm
-1
(neat): 2956 (CH3), 2929 (=CH2), 2163 (C=C), 1728 (C=O of lactone), 
1645 (C=O of ester), 1435 (CH2), 1225 (C-N), 1157, 1005, 902. 
HRMS (ESI+): m/z calculated for C14H19NO6Na [M+Na]
+
 = 320.1105 found = 
320.1101.   
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Methyl 2-((6S,7R,7aS)-3-oxo-6-(prop-1-en-2-yl)hexahydropyrrolo[1,2-c]oxazol-7-
yl)acetate 2.345 
 
 
 
The decarboxylation was performed by a modification of the procedure of Krapcho.
124 
29 mg of NaCl (0.50 mmol) was added to 150 mg (0.46 mmol) of dimethyl 2-
((6S,7S,7aS)-3-oxo-6-(prop-1-en-2-yl)hexahydropyrrolo[1,2-c]oxazol-7-yl)malonate 
2.343 in 12 mL of  hydrated DMSO and heated to   170 
o
C for 8 hours. After cooling 
down to room temperature, the organic layer was extracted with ethyl acetate (3 x 15 
mL) and dried over magnesium sulfate, filtered and concentrated under reduced 
pressure. The residue obtained was subjected to flash column chromatography on silica, 
eluting with (EtOAc/hexane, 2:8) to give 2.345 as orange oil (72 mg, 75%). 
TLC, (EtOAc/Hexane: 1/5) Rf = 0.38. 
[α]D +3.2° (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ: 4.94-4.91 (1H, m, H-14), 4.83 (1H, d, J =8.9 Hz, H-14), 
4.45 (1H, dt, J = 14.6, 7.3 Hz, H-4), 4.36 (1H, td, J = 8.3, 5.1 Hz, H-5), 4.12 (1H, dd, J 
= 9.6, 5.1 Hz, H-4), 3.85 (1H, dd, J = 11.9, 7.2 Hz, H-8), 3.70 (3H, s, H-11), 3.04-2.97 
(1H, dd, J = 11.9, 8.9 Hz, H-8), 2.64-2.55 (1H, m, H-7), 2.48 (1H, dd, J = 16.9, 5.6 Hz, 
H-9), 2.36 (1H, d, J = 6.5 Hz, H-6), 2.35-2.31 (1H, m, H-9), 1.76 (3H, s, H-13). 
13
C NMR (125.7 MHz, CDCl3) δ: 172.4 (C-10), 161.5 (C-2), 142.0 (C-12), 113.4 (C-
14), 64.7 (C-4), 59.6 (C-5), 52.8 (C-7), 52.0 (C-11), 50.1 (C-8), 40.5 (C-6), 33.3 (C-9), 
20.2 (C-13). 
FTIR υmax cm
-1
(neat): 2945 (CH3), 2920 (=CH2), 1730 (C=O of lactone), 1645 (C=O of 
ester), 1437 (CH2), 1378 (CH2),  1207 (C-N), 1169, 1013, 895. 
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HRMS (ESI+): m/z calculated for C12H17NO4Na [M+Na]
+
 = 262.1050 found = 
262.1052.   
 
 
Methyl 2-((6R,7S,7aS)-3-oxo-6-(prop-1-en-2-yl)hexahydropyrrolo[1,2-c]oxazol-7-
yl)acetate 2.233 
            
 
 
The decarboxylation was performed by a modification of the procedure of Krapcho.
124 
29 mg of NaCl (0.50 mmol) was added to 150 mg (0.46 mmol) of dimethyl 2-
((6R,7R,7aS)-3-oxo-6-(prop-1-en-2-yl)hexahydropyrrolo[1,2-c]oxazol-7-yl)malonate 
2.338 in 12 mL of  hydrated DMSO and heated to 170 
o
C for 8 hours. After cooling 
down to room temperature, the organic layer was extracted with ethyl acetate (3 x 15 
mL) and dried over magnesium sulfate, filtered and concentrated under reduced 
pressure. The resulting residue was subjected to flash column chromatography on silica, 
eluting with (EtOAc/hexane, 2:8) to give 2.333 as orange oil (80 mg, 83%). 
TLC, (EtOAc/Hexane: 1/5) Rf = 0.37. 
 [α]D +5.2° (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ: 4.89 (1H, dd, J = 2.9, 1.4 Hz, H-14), 4.87-4.85 (1H, m, 
H-14), 4.52 (1H, dd, J = 9.4, 7.9 Hz, H-4), 4.41 (1H, dd, J = 9.4, 4.2 Hz, H-4), 3.78 (1H, 
ddd, J = 9.2, 8.0, 4.2 Hz, H-5), 3.68 (3H, s, H-11), 3.47 (1H, dd, J = 11.4, 8.9 Hz, H-8), 
3.43-3.37 (1H, m, H-8), 2.73 (1H, dd, J = 19.7, 9.2 Hz, H-7), 2.58 (1H, dd, J = 15.9, 3.7 
Hz, H-9), 2.25-2.18 (1H, m, H-9), 2.12 (1H, ddd, J = 20.3, 9.7, 3.7 Hz, H-6), 1.71 (3H, 
s, H-13). 
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13
C NMR (125.7 MHz, CDCl3) δ: 172.2 (C-10), 160.7 (C-2), 141.2 (C-12), 114.7 (C-
14), 67.7 (C-4), 64.7 (C-5), 55.0 (C-7), 51.8 (C-11), 48.7 (C-8), 43.3 (C-6), 34.9 (C-9), 
18.1  (C-13). 
FTIR υmax cm
-1
(neat): 2953 (CH3), 2918 (=CH2), 1730 (C=O of lactone), 1644 (C=O of 
ester), 1437 (CH2), 1394 (CH2),  1206 (C-N), 1166, 1002, 897. 
HRMS (ESI): m/z calculated for C12H17NO4 [M+Na]
+
 262.1050 found 262.1048.   
 
 
Dimethyl 2-((6S,7S,7aS)-6-acetyl-3-oxohexahydropyrrolo[1,2-c]oxazol-7-yl)-2- 
(phenylselanyl)malonate 2.352 
 
 
 
The selenation was performed by the modification of the procedure of Rubio.
59
 
To a solution of 100 mg (0.31 mmol) dimethyl 2-((6R,7S,7aS)-6-acetyl-3-
oxohexahydropyrrolo[1,2-c]oxazol-7-yl)malonate 2.329,  in Anhydrous THF 10 mL, 
was added a 1M solution of KHMDS (0.35 mL, 1.0 mmol) at 0 
o
C. After 30 min a 
solution of phenylselenyl chloride (45 mg, 1.09 mmol) in 5 mL of THF was added at  0 
o
C. The mixture was stirred overnight at room temperature. The reaction was quenched 
with saturated ammonium chloride solution (10 mL) and extracted with diethyl ether (3 
x 15 mL). The organic phase was dried over MgSO4, filtered and concentrated under 
reduced pressure. The resulting residue was subjected to flash column chromatography 
on silica, eluting with (EtOAc/hexane, 1:6) to give the selenated compound 2.352 as a 
red semi-solid (118 mg, 78%).  
TLC, (EtOAc/hexane 2/5) Rf = 0.42. 
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[α]D -3.2° (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ: 7.54 (2H, m, H-14), 7.47 (1H, m, H-16), 7.38 (2H, m, 
H-15), 4.46-4.37 (2H, m, H-4), 4.35 (1H, dd, J = 12.0, 3.4, H-5), 4.08 (1H, m, H-8), 
3.83-3.71 (6H, m, H-11 and H-13), 3.70 (1H, m, H-7), 3.67 (1H, m, H-6), 2.96 (1H, dt, 
J = 12.7, 6.4, H-8), 2.26 (3H, m, H-18). 
13
C NMR (125.7 MHz, CDCl3) δ: 207.0 (C-17), 168.4 (C-10 and C-12), 159.5 (C-2), 
154.2 (C-9), 137.91 (C-14), 130.6 (C-15), 129.3 (C-16), 64.9 (C-4), 60.8 (C-5), 55.5 (C-
7), 53.9 (C-11 and C-13), 53.2 (C-6), 47.8 (C-8), 30.4 (C-15). 
FTIR    υmax cm
-1
(neat): 2982 (CH3), 1673 (C=O of ester).  
HRMS (ESI): m/z calculated for C19H21NO7Se [M+Na]
+
 478.0375 found 478.0375. 
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 Table 1.  Crystal data and structure refinement for import. 
 
  
     Identification code                   shelxl 
 
     Empirical formula                      C11 H18 I N O4 
 
     Formula weight                         355.16 
 
    Temperature                               173(2) K 
 
    Wavelength                                        0.71073 A 
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    Crystal system, space group           monoclinic,  P 21 
  
  
    Unit cell dimensions                a = 5.6368(3) A   alpha = 90 deg. 
 
                                           b = 9.1663(4) A    beta = 98.970(2) deg. 
 
                                            c = 13.8464(7) A   gamma = 90 deg. 
 
  
      Volume                                 706.67(6) A^3 
 
  
      Z, Calculated density              2,  1.669 Mg/m^3 
 
  
      Absorption coefficient             2.269 mm^-1 
 
  
      F(000)                              352 
 
  
      Crystal size                        0.25 x 0.12 x 0.08 mm 
 
  
      Theta range for data collection   1.49 to 27.42 deg. 
 
  
      Limiting indices                   -7<=h<=7, -9<=k<=11, -17<=l<=12 
 
  
      Reflections collected / unique    4203 / 2869 [R(int) = 0.0474] 
 
  
      Completeness to theta = 27.42     98.5 % 
 
  
     Max. and min. transmission        0.8393 and 0.6008 
 
  
      Refinement method                  Full-matrix least-squares on F^2 
 
  
      Data / restraints / parameters     2869 / 1 / 154 
 
  
      Goodness-of-fit on F^2             1.219 
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      Final R indices [I>2sigma(I)]     R1 = 0.0267, wR2 = 0.0841 
 
  
      R indices (all data)               R1 = 0.0321, wR2 = 0.0975 
  
 
      Absolute structure parameter      0.01(3) 
 
  
      Largest diff. peak and hole       0.783 and -1.181 e.A^-3 
 
  
         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic 
 
         displacement parameters (A^2 x 10^3) for import. 
 
         U(eq) is defined as one third of the trace of the orthogonalized 
 
         Uij tensor. 
 
  
 
         ________________________________________________________________ 
 
  
 
                         x             y             z           U(eq) 
 
         ________________________________________________________________ 
 
  
 
          C(1)         9354(8)       9597(5)       7788(4)       31(1) 
 
          C(2)         9223(8)      10864(6)       8493(3)       29(1) 
 
          C(3)        10255(7)      12135(5)       7955(3)       27(1) 
 
          C(4)        11805(8)       9807(5)       7463(4)       28(1) 
 
          C(5)        11415(7)      13253(5)       8666(3)       26(1) 
 
          C(6)        14949(10)     14137(9)       9614(5)       55(2) 
 
          C(7)        13039(8)      12050(5)       6715(4)       28(1) 
 
          C(8)        13460(7)      14449(5)       5955(3)       26(1) 
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          C(9)        12236(9)      14001(8)       4950(4)       42(1) 
 
          C(10)       12646(9)      15955(6)       6225(5)       39(1) 
 
          C(11)       16199(7)      14416(6)       6052(4)       34(1) 
 
          I(1)         9083(1)       7460(1)       8401(1)       40(1) 
 
          N(1)        11893(7)      11394(4)       7383(3)       29(1) 
 
          O(1)        10303(6)      14223(4)       8969(3)       40(1) 
 
          O(2)        13762(6)      13032(4)       8951(3)       38(1) 
 
          O(3)        12615(6)      13495(4)       6701(3)       29(1) 
 
          O(4)        14300(7)      11393(4)       6219(3)       39(1) 
 
         ________________________________________________________________ 
 
  
           Table 3.  Bond lengths [A] and angles [deg] for import. 
 
           _____________________________________________________________ 
 
  
 
            C(1)-C(2)                     1.526(7) 
 
            C(1)-C(4)                     1.530(6) 
 
            C(1)-I(1)                     2.150(5) 
 
            C(1)-H(1)                     1.0000 
 
            C(2)-C(3)                     1.544(6) 
 
            C(2)-H(2A)                    0.9900 
 
            C(2)-H(2B)                    0.9900 
 
            C(3)-N(1)                     1.472(5) 
 
            C(3)-C(5)                     1.499(7) 
 
            C(3)-H(3)                     1.0000 
 
            C(4)-N(1)                     1.461(6) 
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            C(4)-H(4A)                    0.9900 
 
            C(4)-H(4B)                    0.9900 
 
            C(5)-O(1)                     1.200(6) 
 
            C(5)-O(2)                     1.336(5) 
 
            C(6)-O(2)                     1.457(7) 
 
            C(6)-H(6A)                    0.9800 
 
            C(6)-H(6B)                    0.9800 
 
            C(6)-H(6C)                    0.9800 
 
            C(7)-O(4)                     1.221(6) 
 
            C(7)-O(3)                     1.346(7) 
 
            C(7)-N(1)                     1.350(6) 
 
            C(8)-O(3)                     1.486(5) 
 
            C(8)-C(9)                     1.511(7) 
 
            C(8)-C(10)                    1.520(7) 
 
            C(8)-C(11)                    1.529(5) 
 
            C(9)-H(9A)                    0.9800 
 
            C(9)-H(9B)                    0.9800 
 
            C(9)-H(9C)                    0.9800 
 
            C(10)-H(10A)                  0.9800 
 
            C(10)-H(10B)                  0.9800 
 
            C(10)-H(10C)                  0.9800 
 
            C(11)-H(11A)                  0.9800 
 
            C(11)-H(11B)                  0.9800 
 
            C(11)-H(11C)                  0.9800 
 
137 
 
  
 
            C(2)-C(1)-C(4)              103.2(4) 
 
            C(2)-C(1)-I(1)              115.3(3) 
 
            C(4)-C(1)-I(1)              110.7(3) 
 
            C(2)-C(1)-H(1)              109.2 
 
            C(4)-C(1)-H(1)              109.2 
 
            I(1)-C(1)-H(1)              109.2 
 
            C(1)-C(2)-C(3)              101.9(3) 
 
            C(1)-C(2)-H(2A)             111.4 
 
            C(3)-C(2)-H(2A)             111.4 
 
            C(1)-C(2)-H(2B)             111.4 
 
            C(3)-C(2)-H(2B)             111.4 
 
            H(2A)-C(2)-H(2B)            109.3 
 
            N(1)-C(3)-C(5)              115.0(3) 
 
            N(1)-C(3)-C(2)              103.1(3) 
 
            C(5)-C(3)-C(2)              111.0(4) 
 
            N(1)-C(3)-H(3)              109.2 
 
            C(5)-C(3)-H(3)              109.2 
 
            C(2)-C(3)-H(3)              109.2 
 
            N(1)-C(4)-C(1)              101.0(4) 
 
            N(1)-C(4)-H(4A)             111.6 
 
            C(1)-C(4)-H(4A)             111.6 
 
            N(1)-C(4)-H(4B)             111.6 
 
            C(1)-C(4)-H(4B)             111.6 
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            H(4A)-C(4)-H(4B)            109.4 
 
            O(1)-C(5)-O(2)              123.8(5) 
 
            O(1)-C(5)-C(3)              122.6(4) 
 
            O(2)-C(5)-C(3)              113.6(4) 
 
            O(2)-C(6)-H(6A)             109.5 
 
            O(2)-C(6)-H(6B)             109.5 
 
            H(6A)-C(6)-H(6B)            109.5 
 
            O(2)-C(6)-H(6C)             109.5 
 
            H(6A)-C(6)-H(6C)            109.5 
 
            H(6B)-C(6)-H(6C)            109.5 
 
            O(4)-C(7)-O(3)              126.5(4) 
 
            O(4)-C(7)-N(1)              123.3(4) 
 
            O(3)-C(7)-N(1)              110.2(4) 
 
            O(3)-C(8)-C(9)              109.3(4) 
 
            O(3)-C(8)-C(10)             102.9(3) 
 
            C(9)-C(8)-C(10)             111.1(4) 
 
            O(3)-C(8)-C(11)             110.9(3) 
 
            C(9)-C(8)-C(11)             112.7(4) 
 
            C(10)-C(8)-C(11)            109.6(4) 
 
            C(8)-C(9)-H(9A)             109.5 
 
            C(8)-C(9)-H(9B)             109.5 
 
            H(9A)-C(9)-H(9B)            109.5 
 
            C(8)-C(9)-H(9C)             109.5 
 
            H(9A)-C(9)-H(9C)            109.5 
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            H(9B)-C(9)-H(9C)            109.5 
 
            C(8)-C(10)-H(10A)           109.5 
 
            C(8)-C(10)-H(10B)           109.5 
 
            H(10A)-C(10)-H(10B)         109.5 
 
            C(8)-C(10)-H(10C)           109.5 
 
            H(10A)-C(10)-H(10C)         109.5 
 
            H(10B)-C(10)-H(10C)         109.5 
 
            C(8)-C(11)-H(11A)           109.5 
 
            C(8)-C(11)-H(11B)           109.5 
 
            H(11A)-C(11)-H(11B)         109.5 
 
            C(8)-C(11)-H(11C)           109.5 
 
            H(11A)-C(11)-H(11C)         109.5 
 
            H(11B)-C(11)-H(11C)         109.5 
 
            C(7)-N(1)-C(4)              121.4(4) 
 
            C(7)-N(1)-C(3)              124.8(4) 
 
            C(4)-N(1)-C(3)              112.8(3) 
 
            C(5)-O(2)-C(6)              114.6(4) 
 
            C(7)-O(3)-C(8)              120.9(4) 
 
           _____________________________________________________________ 
 
  
 
           Symmetry transformations used to generate equivalent atoms: 
 
            
    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for import. 
 
    The anisotropic displacement factor exponent takes the form: 
 
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ] 
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______________________________________________________________________
_ 
 
  
 
              U11        U22        U33        U23        U13        U12 
 
    
______________________________________________________________________
_ 
 
  
 
    C(1)     36(2)      28(3)      30(2)       2(2)      10(2)      -2(2) 
 
    C(2)     36(2)      28(3)      26(3)       1(2)      12(2)       0(2) 
 
    C(3)     27(2)      26(3)      30(2)       3(2)      15(2)       5(2) 
 
    C(4)     36(2)      19(2)      32(2)       6(2)      11(2)       3(2) 
 
    C(5)     30(2)      23(2)      28(2)       6(2)      13(2)       4(2) 
 
    C(6)     38(2)      79(5)      49(3)     -20(3)      12(2)     -18(3) 
 
    C(7)     29(2)      30(3)      25(2)      -1(2)       9(2)      -1(2) 
 
    C(8)     21(2)      32(3)      25(2)       8(2)       6(2)      -3(2) 
 
    C(9)     37(2)      59(4)      29(2)       6(3)       1(2)     -12(2) 
 
    C(10)    35(2)      30(3)      52(3)      13(2)      10(2)       2(2) 
 
    C(11)    23(2)      33(3)      47(3)       6(2)       8(2)      -1(2) 
 
    I(1)     60(1)      24(1)      39(1)      -1(1)      18(1)     -10(1) 
 
    N(1)     39(2)      21(2)      31(2)       4(2)      19(2)       3(2) 
 
    O(1)     41(2)      27(2)      56(2)      -6(2)      21(2)       1(2) 
 
    O(2)     32(2)      47(2)      36(2)     -10(2)      11(1)       2(1) 
 
    O(3)     35(2)      24(2)      30(2)       5(2)      13(1)       3(1) 
 
141 
 
    O(4)     52(2)      32(2)      38(2)       0(2)      26(2)       3(2) 
 
    
______________________________________________________________________
_ 
Table 5.  Torsion angles [deg] for import. 
 
         ________________________________________________________________ 
 
  
 
 
 
 
       
Table 1.  Crystal data and structure refinement for import. 
 
  
 
  
 
      Identification code                shelxl 
 
  
      Empirical formula                  C13 H14 Cl N O5 S 
 
  
      Formula weight              331.76 
  
 
      Temperature                     173(2) K 
 
  
      Wavelength                        0.71073 A 
 
  
      Crystal system, space group        monoclinic,  P21/c 
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      Unit cell dimensions             a = 11.4168(2) A   alpha = 90 deg. 
 
                                          b = 6.24090(10) A beta = 103.7490(10) deg. 
   
                                         c = 20.3795(4) A   gamma = 90 deg. 
 
 
      Volume                           1410.45(4) A^3 
 
  
      Z, Calculated density            4,  1.562 Mg/m^3 
 
  
      Absorption coefficient            0.440 mm^-1 
  
  
      F(000)                            688 
 
  
      Crystal size                         0.30 x 0.20 x 0.15 mm 
 
  
      Theta range for data collection   3.42 to 27.87 deg. 
 
  
      Limiting indices                  -14<=h<=14, -7<=k<=8, -25<=l<=26 
 
 
      Reflections collected / unique     18724 / 3176 [R(int) = 0.0656] 
 
  
      Completeness to theta = 27.87       94.6 % 
 
  
      Max. and min. transmission       0.9370 and 0.8794 
 
  
      Refinement method            Full-matrix least-squares on F^2 
 
  
      Data / restraints / parameters    3176 / 0 / 190 
 
  
      Goodness-of-fit on F^2              1.226 
 
  
      Final R indices [I>2sigma(I)]       R1 = 0.0646, wR2 = 0.1964 
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      R indices (all data)                R1 = 0.0761, wR2 = 0.2021 
 
 
      Largest diff. peak and hole     0.630 and -0.456 e.A^-3 
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       Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic 
 
         displacement parameters (A^2 x 10^3) for import. 
 
         U(eq) is defined as one third of the trace of the orthogonalized 
 
         Uij tensor. 
 
  
 
         ________________________________________________________________ 
 
  
 
                         x             y             z           U(eq) 
 
         ________________________________________________________________ 
 
  
 
          O(5)        10292(3)       2226(5)       4355(1)       24(1) 
 
          C(2)         9855(4)       1341(6)       3677(2)       22(1) 
 
          C(3)         8897(4)       2812(6)       3261(2)       24(1) 
 
          C(4)         7778(4)       2207(6)       3508(2)       23(1) 
 
          C(6)         9190(4)       -745(7)       3758(2)       26(1) 
 
          C(7)         6526(4)       2379(7)       3040(3)       34(1) 
 
          C(8)         7107(4)      -1160(7)       3100(2)       26(1) 
 
          C(12)       12562(4)       1768(7)       4354(2)       24(1) 
 
          C(13)       12848(4)         53(8)       4797(2)       30(1) 
 
          C(14)       13632(4)      -1500(8)       4682(2)       32(1) 
 
          C(15)       14141(4)      -1384(8)       4122(2)       30(1) 
 
          C(16)       13848(4)        359(8)       3687(2)       30(1) 
 
          C(17)       13054(4)       1935(7)       3795(2)       27(1) 
 
          C(18)       14970(4)      -3106(9)       3987(3)       39(1) 
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          Cl(1)        8723(1)       2102(2)       2391(1)       34(1) 
 
          N(1)         7916(3)       -116(5)       3608(2)       21(1) 
 
          O(1)        11344(3)       5272(5)       3980(2)       33(1) 
 
          O(2)        11705(3)       4173(5)       5180(2)       33(1) 
 
          O(3)         6225(3)        209(5)       2793(2)       31(1) 
 
          O(4)         7128(3)      -3007(5)       2940(2)       35(1) 
 
          S(1)        11487(1)       3636(2)       4483(1)       24(1) 
 
         ________________________________________________________________ 
 
  
 
           Table 3.  Bond lengths [A] and angles [deg] for import. 
 
           _____________________________________________________________ 
 
  
 
            O(5)-C(2)                     1.462(4) 
 
            O(5)-S(1)                     1.592(3) 
 
            C(2)-C(3)                     1.522(6) 
 
            C(2)-C(6)                     1.536(6) 
 
            C(2)-H(2)                     1.0000 
 
            C(3)-C(4)                     1.527(6) 
 
            C(3)-Cl(1)                    1.793(4) 
 
            C(3)-H(3)                     1.0000 
 
            C(4)-N(1)                     1.467(5) 
 
            C(4)-C(7)                     1.521(6) 
 
            C(4)-H(4)                     1.0000 
 
            C(6)-N(1)                     1.467(5) 
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            C(6)-H(6A)                    0.9900 
 
            C(6)-H(6B)                    0.9900 
 
            C(7)-O(3)                     1.457(5) 
 
            C(7)-H(7A)                    0.9900 
 
            C(7)-H(7B)                    0.9900 
 
            C(8)-O(4)                     1.199(5) 
 
            C(8)-O(3)                     1.354(5) 
 
            C(8)-N(1)                     1.377(5) 
 
            C(12)-C(13)                   1.387(6) 
 
            C(12)-C(17)                   1.389(6) 
 
            C(12)-S(1)                    1.756(4) 
 
            C(13)-C(14)                   1.376(7) 
 
            C(13)-H(13)                   0.9500 
 
            C(14)-C(15)                   1.401(6) 
 
            C(14)-H(14)                   0.9500 
 
            C(15)-C(16)                   1.393(7) 
 
            C(15)-C(18)                   1.500(7) 
 
            C(16)-C(17)                   1.390(6) 
 
            C(16)-H(16)                   0.9500 
 
            C(17)-H(17)                   0.9500 
 
            C(18)-H(18A)                  0.9800 
 
            C(18)-H(18B)                  0.9800 
 
            C(18)-H(18C)                  0.9800 
 
            O(1)-S(1)                     1.429(3) 
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            O(2)-S(1)                     1.423(3) 
 
  
 
            C(2)-O(5)-S(1)              116.7(2) 
 
            O(5)-C(2)-C(3)              109.6(3) 
 
            O(5)-C(2)-C(6)              106.5(3) 
 
            C(3)-C(2)-C(6)              105.2(3) 
 
            O(5)-C(2)-H(2)              111.7 
 
            C(3)-C(2)-H(2)              111.7 
 
            C(6)-C(2)-H(2)              111.7 
 
            C(2)-C(3)-C(4)              102.4(3) 
 
            C(2)-C(3)-Cl(1)             107.3(3) 
 
            C(4)-C(3)-Cl(1)             111.1(3) 
 
            C(2)-C(3)-H(3)              111.9 
 
            C(4)-C(3)-H(3)              111.9 
 
            Cl(1)-C(3)-H(3)             111.9 
 
            N(1)-C(4)-C(7)              102.2(3) 
 
            N(1)-C(4)-C(3)              102.7(3) 
 
            C(7)-C(4)-C(3)              120.8(4) 
 
            N(1)-C(4)-H(4)              110.1 
 
            C(7)-C(4)-H(4)              110.1 
 
            C(3)-C(4)-H(4)              110.1 
 
            N(1)-C(6)-C(2)              104.0(3) 
 
            N(1)-C(6)-H(6A)             111.0 
 
            C(2)-C(6)-H(6A)             111.0 
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            N(1)-C(6)-H(6B)             111.0 
 
            C(2)-C(6)-H(6B)             111.0 
 
            H(6A)-C(6)-H(6B)            109.0 
 
            O(3)-C(7)-C(4)              105.1(3) 
 
            O(3)-C(7)-H(7A)             110.7 
 
            C(4)-C(7)-H(7A)             110.7 
 
            O(3)-C(7)-H(7B)             110.7 
 
            C(4)-C(7)-H(7B)             110.7 
 
            H(7A)-C(7)-H(7B)            108.8 
 
            O(4)-C(8)-O(3)              122.8(4) 
 
            O(4)-C(8)-N(1)              127.3(4) 
 
            O(3)-C(8)-N(1)              109.9(3) 
 
            C(13)-C(12)-C(17)           120.8(4) 
 
            C(13)-C(12)-S(1)            118.7(3) 
 
            C(17)-C(12)-S(1)            120.3(3) 
 
            C(14)-C(13)-C(12)           119.7(4) 
 
            C(14)-C(13)-H(13)           120.2 
 
            C(12)-C(13)-H(13)           120.2 
 
            C(13)-C(14)-C(15)           121.0(4) 
 
            C(13)-C(14)-H(14)           119.5 
 
            C(15)-C(14)-H(14)           119.5 
 
            C(16)-C(15)-C(14)           118.4(4) 
 
            C(16)-C(15)-C(18)           120.7(4) 
 
            C(14)-C(15)-C(18)           121.0(4) 
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            C(17)-C(16)-C(15)           121.3(4) 
 
            C(17)-C(16)-H(16)           119.4 
 
            C(15)-C(16)-H(16)           119.4 
 
            C(12)-C(17)-C(16)           118.9(4) 
 
            C(12)-C(17)-H(17)           120.6 
 
            C(16)-C(17)-H(17)           120.6 
 
            C(15)-C(18)-H(18A)          109.5 
 
            C(15)-C(18)-H(18B)          109.5 
 
            H(18A)-C(18)-H(18B)         109.5 
 
            C(15)-C(18)-H(18C)          109.5 
 
            H(18A)-C(18)-H(18C)         109.5 
 
            H(18B)-C(18)-H(18C)         109.5 
 
            C(8)-N(1)-C(6)              119.0(3) 
 
            C(8)-N(1)-C(4)              109.4(3) 
 
            C(6)-N(1)-C(4)              111.2(3) 
 
            C(8)-O(3)-C(7)              109.8(3) 
 
            O(2)-S(1)-O(1)              120.7(2) 
 
            O(2)-S(1)-O(5)              103.48(17) 
 
            O(1)-S(1)-O(5)              109.31(18) 
 
            O(2)-S(1)-C(12)             110.01(19) 
 
            O(1)-S(1)-C(12)             109.4(2) 
 
            O(5)-S(1)-C(12)             102.19(18) 
 
           _____________________________________________________________ 
 
  
           Symmetry transformations used to generate equivalent atoms: 
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     Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for import. 
 
    The anisotropic displacement factor exponent takes the form: 
 
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ] 
 
  
 
    
______________________________________________________________________
_ 
 
  
 
              U11        U22        U33        U23        U13        U12 
 
    
______________________________________________________________________
_ 
 
  
 
    O(5)     27(1)      27(2)      19(1)      -3(1)       5(1)      -2(1) 
 
    C(2)     24(2)      23(2)      20(2)      -5(2)       6(2)      -2(2) 
 
    C(3)     30(2)      18(2)      24(2)       2(2)       4(2)      -4(2) 
 
    C(4)     26(2)      14(2)      29(2)      -3(2)       6(2)       0(2) 
 
    C(6)     30(2)      15(2)      32(2)      -1(2)       5(2)      -1(2) 
 
    C(7)     31(2)      19(2)      47(3)      -4(2)       3(2)       0(2) 
 
    C(8)     27(2)      22(2)      29(2)       0(2)       9(2)      -4(2) 
 
    C(12)    23(2)      24(2)      23(2)      -2(2)       3(2)      -3(2) 
 
    C(13)    33(2)      36(2)      22(2)       4(2)       8(2)      -2(2) 
 
    C(14)    32(2)      33(2)      30(2)       6(2)       4(2)       0(2) 
 
    C(15)    23(2)      34(2)      30(2)      -9(2)       2(2)      -8(2) 
 
    C(16)    29(2)      36(2)      25(2)      -5(2)       9(2)      -9(2) 
 
    C(17)    28(2)      31(2)      21(2)       1(2)       3(2)      -7(2) 
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    C(18)    35(2)      42(3)      41(3)      -9(2)       9(2)       1(2) 
 
    Cl(1)    41(1)      40(1)      20(1)       1(1)       7(1)      -9(1) 
 
    N(1)     28(2)      14(2)      20(2)      -2(1)       7(1)       0(1) 
 
    O(1)     42(2)      27(2)      28(2)       5(1)       4(1)      -3(1) 
 
    O(2)     40(2)      35(2)      20(1)      -7(1)       2(1)      -1(1) 
 
    O(3)     27(2)      21(2)      41(2)      -4(1)      -1(1)      -4(1) 
 
    O(4)     44(2)      18(2)      41(2)      -9(1)       7(1)      -7(1) 
 
    S(1)     29(1)      24(1)      19(1)      -2(1)       3(1)      -4(1) 
 
    
______________________________________________________________________
_ 
 
  
 
         Table 5.  Torsion angles [deg] for import. 
 
         ________________________________________________________________ 
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